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A B S T R A C T
Background
Typhoid fever and paratyphoid fever continue to be important causes of illness and death, particularly among children and adolescents
in south-central and southeast Asia. Two typhoid vaccines are commercially available, Ty21a (oral) and Vi polysaccharide (parenteral),
but neither is used routinely. Other vaccines, such as a new, modified, conjugated Vi vaccine called Vi-rEPA, are in development.
Objectives
To evaluate the efficacy and adverse effects of vaccines used to prevent typhoid fever.
Search methods
In June 2013, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS,
and mRCT. We also searched relevant conference proceedings up to 2013 and scanned the reference lists of all included trials.
Selection criteria
Randomized and quasi-randomized controlled trials (RCTs) comparing typhoid fever vaccines with other typhoid fever vaccines or
with an inactive agent (placebo or vaccine for a different disease).
Data collection and analysis
Two review authors independently applied inclusion criteria and extracted data. We computed vaccine efficacy per year of follow-up
and cumulative three-year efficacy, stratifying for vaccine type and dose. The outcome addressed was typhoid fever, defined as isolation
of Salmonella typhi in blood. We calculated risk ratios (RRs) and efficacy (1-RR as a percentage) with 95% confidence intervals (CIs).
Main results
In total, 18 RCTs were included in this review; 12 evaluated efficacy (Ty21a: five trials; Vi polysaccharide: six trials; Vi-rEPA: one trial),
and 11 reported on adverse events.
Ty21a vaccine (oral vaccine, three doses)
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A three-dose schedule of Ty21a vaccine prevents around one-third to one-half of typhoid cases in the first two years after vaccination
(Year 1: 35%, 95% CI 8% to 54%; Year 2: 58%, 95% CI 40% to 71%; one trial, 20,543 participants; moderate quality evidence;
data taken from a single trial conducted in Indonesia in the 1980s). No benefit was detected in the third year after vaccination. Four
additional cluster-RCTs have been conducted, but the study authors did not adjust for clustering.
Compared with placebo, this vaccine was not associated with more participants with vomiting, diarrhoea, nausea or abdominal pain
(four trials, 2066 participants; moderate quality evidence) headache, or rash (two trials, 1190 participants; moderate quality evidence);
however, fever (four trials, 2066 participants; moderate quality evidence) was more common in the vaccine group.
Vi polysaccharide vaccine (injection, one dose)
A single dose of Vi polysaccharide vaccine prevents around two-thirds of typhoid cases in the first year after vaccination (Year 1: 69%,
95% CI 63% to 74%; three trials, 99,979 participants; high quality evidence). In Year 2, the trial results were more variable, with the
vaccine preventing between 45% and 69% of typhoid cases (Year 2: 59%, 95% CI 45% to 69%; four trials, 194,969 participants;
moderate quality evidence). The three-year cumulative efficacy of the vaccine is around 55% (95% CI 30% to 70%; 11,384 participants,
one trial; moderate quality evidence). These data are taken from a single trial in South Africa in the 1980s.
Compared with placebo, this vaccine was not associated with more participants with fever (four trials, 133,038 participants; moderate
quality evidence) or erythema (three trials, 132,261 participants; low quality evidence); however, swelling (three trials, 1767 participants;
moderate quality evidence) and pain at the injection site (one trial, 667 participants; moderate quality evidence) were more common in
the vaccine group.
Vi-rEPA vaccine (two doses)
Administration of two doses of the Vi-rEPA vaccine prevents between 50% and 96% of typhoid cases during the first two years after
vaccination (Year 1: 94%, 95% CI 75% to 99%; Year 2: 87%, 95% CI 56% to 96%; one trial, 12,008 participants; moderate quality
evidence). These data are taken from a single trial with children 2 to 5 years of age conducted in Vietnam.
Compared with placebo, the first and second doses of this vaccine were not associated with increased risk of adverse events. The first
dose of this vaccine was not associated with fever (2 studies, 12,209 participants; low quality evidence), erythema (two trials, 12,209
participants; moderate quality evidence) or swelling at the injection site (two trials, 12,209 participants; moderate quality evidence).
The second dose of this vaccine was not associated with fever (two trials, 11,286 participants; low quality evidence), erythema (two
trials, 11,286 participants; moderate quality evidence) and swelling at the injection site (two trials, 11,286 participants; moderate quality
evidence).
Authors’ conclusions
The licensed Ty21a and Vi polysaccharide vaccines are efficacious. The new and unlicensed Vi-rEPA vaccine is as efficacious and may
confer longer immunity.
P L A I N L A N G U A G E S U M M A R Y
Ty21a and Vi polysaccharide vaccines are effective in reducing typhoid fever; new vaccines are promising
Typhoid fever is a bacterial infection found mainly among children and adolescents in south and east Asia, Africa, Latin America
and the Caribbean. Typhoid fever is spread by food, drink, or contaminated water. It is characterized by fever, abdominal symptoms,
headache, loss of appetite, cough, weakness, sore throat, dizziness and muscle pains. The infection also sometimes causes psychosis and
confusion. Mortality varies and can reach 10% of cases. Treatment normally consists of antibiotics, but problems with drug-resistant
strains have been reported. Improved sanitation and food hygiene are important control measures. However, these are associated with
socioeconomic progress that has been slow in most affected areas. Therefore vaccination is an effective way to try to prevent this disease.
The review found 18 trials (17 with usable data): Six evaluated vaccine effectiveness only; six evaluated vaccine effectiveness and adverse
events; and six provided data only on adverse events. The two major vaccines currently licensed for use, Ty21a and Vi polysaccharide,
were effective in reducing typhoid fever; adverse events such as nausea, vomiting and fever were rare. Other vaccines, such as a new,
modified, conjugated Vi vaccine called Vi-rEPA, are in development and appear promising. A vaccine that could be given to infants
would be helpful as they are probably at increased risk of this infection.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ty21a vaccine (3 doses) compared with control; efficacy for preventing typhoid fever
Patient or population: adults and children aged 5 years of age and older
Settings: any
Intervention: Ty21a vaccine (3 doses)
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Ty21a vaccine
Incidence of typhoid
fever, Year 1
Moderate1 RR 0.65
(0.46 to 0.92)
20,543
(1 study, 2 arms)
⊕⊕⊕©
moderate2,3,4,5
Additional cluster-ran-
domized studies have
evaluated this vaccine but
did not adjust for the
effect of clustering and
therefore were not in-
cluded in the meta-analy-
sis
4 per 10,000 3 per 10,000
(2 to 4)
High1
59 per 10,000 38.4 per 10,000
(27.1 to 54.3)
Incidence of typhoid
fever, Year 2
Moderate1 RR 0.42
(0.29 to 0.6)
20,543
(1 study, 2 arms)
⊕⊕⊕©
moderate2,4,5,6
4 per 10,000 1.7 per 10,000
(1.2 to 2.4)
High1
59 per 10,000 24.8 per 10,000
(17.1 to 35.4)
Serious adverse events See comment See comment Not estimable 2620
(3 studies, 5 arms)
See comment No serious adverse
events were reported
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Fever 17 per 1000 25 per 1000
(14 to 45)
RR 1.53
(0.86 to 2.72)
2066
(2 studies, 4 arms)
⊕⊕⊕©
moderate2,7,8
Rash 4 per 1000 8 per 1000
(2 to 28)
RR 1.89
(0.56 to 6.43)
1190
(2 studies, 4 arms)
⊕⊕⊕©
moderate2,8,9
Vomiting 25 per 1000 15 per 1000
(7 to 31)
RR 0.61
(0.3 to 1.24)
2066
(1 study, 2 arms)
⊕⊕⊕©
moderate2,8,10
Any mild adverse event 70 per 1000 117 per 1000
(72 to 191)
RR 1.67
(1.03 to 2.72)
1360
(2 studies, 3 arms)
⊕⊕⊕©
moderate2,11,12
*The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1The incidence of typhoid in a medium -risk setting is taken from the control group in a study from china (Yang 2001 CHN).The incidence
of typhoid in a high-risk setting is taken from a study in India (Sur 2009 IND). This is consistent with the incidence levels described
by a global epidemiological study (Crump 2004).
2No serious risk of bias detected.
3No serious inconsistency: The result was consistent across the two trials (I2 = 0).
4Downgraded by 1 for indirectness: The vaccine has been evaluated only in trials from one endemic setting (Indonesia).
5No serious imprecision: The result is statistically significant with a narrow 95% confidence interval. The meta-analysis is adequately
powered to detect this effect.
6No serious inconsistency: The result was consistent across the two trials (I2 = 1%).
7No serious inconsistencies: The results were consistent across the 5 trials (I2 = 0).
8Downgraded by 1 for serious imprecision: The result is not statistically significant.
9No serious inconsistency: The results were consistent across the three trials (I2 = 0).
10No serious inconsistency.
11Downgraded by 1 for indirectness: The vaccine has been evaluated only in trials from high-incidence settings (Indonesia and Thailand).
12No serious imprecision: The result is statistically significant with a narrow 95% confidence interval.
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B A C K G R O U N D
Description of the condition
Epidemiology
Typhoid fever remains an important global public health problem.
It is estimated that typhoid fever has caused 21.7 million illnesses
and 217,000 deaths worldwide (Crump 2004). However, this is
likely to be a conservative estimate because availability of diagnos-
tic testing and surveillance is limited, and the burden of typhoid
fever is unknown in many developing countries (Crump 2010).
The highest burden of typhoid fever is seen in south-central and
south-eastern Asia (Crump 2004). Recent large population-based
surveillance studies conducted in five Asian countries (China, In-
dia, Indonesia, Pakistan and Vietnam) have confirmed the high
incidence of typhoid fever in the region (Ochiai 2008). Typhoid
fever incidence in sub-Saharan Africa is poorly described; histor-
ically, typhoid fever within the region has been thought to occur
in the form of outbreaks rather than as endemic disease. However,
a recent population-based surveillance study conducted in Kenya
found a high incidence of typhoid fever among children in ur-
ban settings, with rates similar to those seen in south-central and
south-eastern Asia (Breiman 2012). Typhoid fever is rare in in-
dustrialized nations, although travellers to endemic countries are
at risk of acquiring the disease (Bennish 1995).
Until recently, the common view was that typhoid fever mainly
affects children of school age and adults. However, it is now recog-
nized that typhoid fever is an important cause of morbidity among
younger children in areas of high incidence (Ochiai 2008; Sinha
1999; Saha 2001).
Clinical features
Typhoid fever is a systemic infection caused by the Gram-negative
bacterium Salmonella enterica serotype typhi (S. typhi). S. typhi is
spread by food, drink or water contaminated by faecal or urinary
carriers excreting the bacteria. After ingestion, the bacteria spread
from the intestine via the blood, where they multiply to the in-
testinal lymph nodes, liver and spleen. Typhoid fever is character-
ized by fever and abdominal symptoms. Nonspecific symptoms
such as chills, perspiration, diarrhoea or constipation, headache,
anorexia, cough, weakness, sore throat, dizziness and muscle pains
are frequently present before the onset of fever in typhoid. Neu-
ropsychiatric manifestations, including psychosis and confusion,
occur in 5% to 10% of those with typhoid fever. Other symptoms
include bradycardia, rose spots, hepatomegaly, and splenomegaly
(Mandell 2005).
Complications occur in 10% to 15% of patients, usually in the
third and fourth weeks of infection. The most important compli-
cations are gastrointestinal bleeding, intestinal perforation and ty-
phoid encephalopathy. Gastrointestinal bleeding is the most com-
mon, occurring in up to 10% of patients (Parry 2002). Estimates
of case-fatality rates in typhoid fever range from 1% to 4%; fatality
rates in children younger than 4 years of age are 10 times higher
than in older children. In untreated cases, the fatality rates may
rise to 10% to 20% (Bhutta, 1996).
Diagnosis and treatment
Confirmation of typhoid fever requires isolation of S. typhi from
blood, bone marrow, stool or duodenal fluid; blood culture is the
most common method of diagnosis. The Widal test identifies the
agglutinating antibodies against the O (somatic) and H (flagellar)
S. typhi antigens, which appear a week to 10 days after disease on-
set. However, the high numbers of false-positive and false-negative
Widal test results limit its clinical usefulness (Bhan 2005).
Typhoid fever is treated with antibiotics. Increased case-fatality
rates have been associated with multidrug-resistant strains and de-
lays in antimicrobial therapy. Chloramphenicol was for a long time
the preferred treatment for typhoid fever, but owing to substantial
relapse rates and the development of bacterial resistance during
the 1970s and 1980s, this drug was widely replaced by ampicillin
and co-trimoxazole. More recently, increasing resistance to the lat-
ter antibiotics has prompted the use of quinolone derivatives and
third-generation cephalosporins (WHO 2008).
Potential control measures
As humans are the only source of infection and because of the
route of transmission, improved sanitation and food hygiene are
important control measures. However, these measures are associ-
ated with socioeconomic progress that has been slow in most en-
demic areas. Furthermore, achieving control of typhoid fever by
antimicrobial treatment alone requires well-functioning medical
services and is hindered by the increasing problem of antibiotic-
resistant S. typhi. Therefore vaccination against typhoid fever is a
key control measure in high-risk areas (WHO 2008). In addition
to the populations residing in areas in which typhoid fever is en-
demic, travellers to these regions as well as household contacts of
typhoid fever carriers and laboratory workers may benefit from an
effective vaccine (Parry 2002).
Description of the intervention
Typhoid vaccines
Vaccination against typhoid fever is a key control measure; how-
ever, although they have been evaluated among populations in
endemic middle- and low-income countries, typhoid fever vac-
cines have been used predominantly among travellers from high-
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income countries. This situation is changing, thanks to the avail-
ability of high-quality burden of disease data from endemic coun-
tries (Ochiai 2008) and to the experience of typhoid vaccina-
tion programs in Thailand, China, Vietnam and India (DeRoeck,
2008), and of vaccine demonstration projects in five Asian coun-
tries (Ochiai, 2007). A 2008World Health Organization (WHO)
position paper on the use of typhoid vaccines concluded that given
the continued high burden of disease and increasing antibiotic
resistance, countries should consider the programmatic use of ty-
phoid vaccines for controlling endemic disease (WHO2008). De-
spite this recommendation, very few typhoid endemic countries
have implemented a typhoid vaccination programme (Maurice,
2012).
Two typhoid vaccines are currently available internationally: the
live oral Ty21a vaccine (an attenuated strain of S. typhi) and
the parenteral Vi polysaccharide (based on the purified capsular
polysaccharide S. typhi Vi antigen).
Researchers are working to develop a low-cost typhoid vaccine that
is effective in children younger than two years, and that can there-
fore be incorporated into the infant EPI (Expanded Programme
on Immunization) schedule. Typhoid vaccine development is cur-
rently moving in two main directions: the development of Vi con-
jugate vaccines, and the development of an improved live oral vac-
cine (WHO 2008).
Inactivated whole-cell typhoid vaccine
Vaccines of this type were introduced in 1896 (WHO 2005).
Their efficacy was established only in 1960 in controlled trials
in Yugoslavia, the Soviet Union, Poland and Guyana. The 1998
version of this Cochrane Review demonstrated that two doses
of this type of vaccine resulted in 73% efficacy over three years
(95% confidence interval 65% to 80%) (Engels 1998a). Different
methods of inactivating cells of S. typhi have been used to prepare
these vaccines: acetone-inactivated, alcohol-inactivated or heat-
inactivated and phenol preserved. In field trials, the vaccine has
been associated with fever and systemic reactions in 9% to 34%
of recipients, and with short absences from work or school in 2%
to 17% of cases (WHO 2000). Therefore, the inactivated whole-
cell typhoid vaccine is considered unsuitable for use as a public
health vaccine, and, although licensed, it is no longer available for
use (Garmory 2002). Consequently, we have not included killed
whole-cell vaccines in this update.
Ty2la vaccine
This live oral vaccine is available as an enteric-coated capsule or
liquid formulation. It is given in three doses every other day and is
approved for use in children at least 5 years of age. It elicits protec-
tion that starts 10 to 14 days after the third dose. Travellers should
be revaccinated annually, and those living in disease endemic areas
every three years. A theoretical question associated with the Ty21a
vaccine is whether it reverts to virulence; however, such hypothet-
ical effects have never been documented in any of the multiple
large field trials conducted (WHO 2008).
The 2007 version of this Cochrane review found that compared
with placebo, the TY21a vaccine provided statistically significant
protection over the first three years following vaccination, and
that this vaccine was not associated with an increased rate of mild
adverse events (Fraser 2007a).
Vi polysaccharide vaccine
The Vi polysaccharide vaccine is given as a single parenteral dose.
Protection begins seven days after injection, and maximum pro-
tection is reached 28 days after injection, when the highest anti-
body concentration is attained (Garmory 2002). This vaccine is
approved for persons of 2 years of age and older. Revaccination
every three years is recommended.
The 2007 version of this Cochrane review found that this vaccine
provided protection in Year 1 and in Year 2 but not in Year 3
(Fraser 2007a).
Vi-rEPA vaccine
A new, modified Vi vaccine conjugated to a nontoxic recombinant
Pseudomonas aeruginosa exotoxin A (rEPA) has been evaluated in a
randomized controlled trial (RCT) among children 2 to 5 years of
age. This vaccine (Vi-rEPA) has the potential of being immuno-
genic in infants younger than age 2 (Parry 2002). However, this
prototype vaccine is not yet licensed.
Why it is important to do this review
This update of the 2007 Cochrane Review (Fraser 2007a) provides
a more accurate assessment of the efficacy and safety of vaccines to
prevent typhoid fever by incorporating data from new trials. We
would have included head-on comparisons of vaccines had these
been conducted.
O B J E C T I V E S
To evaluate the efficacy and adverse effects of vaccines used to
prevent typhoid fever.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomized and quasi-randomized controlled trials.
Types of participants
Adults and children.
Types of interventions
Intervention
• Typhoid fever vaccines (live oral vaccine Ty2la or genetic
modifications of this strain, Vi polysaccharide vaccine, and Vi
conjugate vaccine).
Control
• Other typhoid fever vaccines or inactive agents (placebo or
vaccine for a different disease).
Excluded
• Trials evaluating killed whole-cell vaccines, because these
vaccines are no longer in use. Trials assessing only adverse events
but not efficacy (the number of typhoid fever cases prevented) of
experimental vaccines that have not yet been evaluated for
efficacy. We excluded trials that reported only on adverse events
while comparing different brands of the same type of typhoid
vaccine.
Types of outcome measures
Primary outcomes
Cases of typhoid fever
Cases of typhoid fever were defined by isolation of S. typhi from a
blood culture.
Secondary outcomes
Adverse events
Serious adverse events (leading to death, requiring inpatient hos-
pitalization or prolonged existing hospitalization, life threatening,
or resulting in persistent or significant disability or incapacity).
Other adverse events (eg fever, erythema at injection site, vomit-
ing, diarrhoea).
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press and in
progress).
Databases
We searched the following databases using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register (June 2013); Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), published in The Cochrane
Library (2013);MEDLINE (1966 to June 2013); EMBASE (1974
to June 2013); and LILACS (1982 to June 2013).We also searched
themetaRegister of Controlled Trials (mRCT) using ’typhoid’ and
’vaccine’ as search terms. We searched the Internet for new drug
application (NDA) documents of the US Food and Drug Admin-
istration, which may include unpublished studies.
Conference proceedings
We searched the following conference proceedings for relevant
abstracts: Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC; 1995 to 2013); European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID; 2001
to 2013); and the Annual Meeting of the Infectious Diseases So-
ciety of America (IDSA; 2001 to 2013).
Reference lists
We checked the reference lists of the included trials.
Data collection and analysis
We used standard methodological procedures as expected by The
Cochrane Collaboration.
Selection of studies
We (E Anwar, E Goldberg and M Paul) independently inspected
titles and abstracts identified by the literature search to identify
potentially relevant publications. Potentially relevant articles, ac-
cording to at least one review author, were obtained in full-text
format. We applied the inclusion criteria for the final decision re-
garding eligibility. We also checked that trials were independent,
that is, we looked for multiple publications of the same trial and
made sure that we included each trial only once. We resolved dis-
agreements by discussion and consensus. Reasons for excluding
studies from the review were documented. We attempted to con-
tact trial authors for clarification if it was unclear whether a po-
tentially relevant trial was eligible for the review.
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Data extraction and management
We (E Anwar and E Goldberg) independently extracted data into
a standard form; a third review author (M Paul) extracted the
data in cases of disagreement. We discussed data extraction, docu-
mented decisions and, when necessary, contacted the trial authors
for clarification or additional details. E Anwar entered data into
Review Manager 5. We aimed to extract data according to an in-
tention-to-treat analysis. If a discrepancy was noted in the number
randomly assigned and the numbers analyzed in each treatment
group, we reported this information. We recorded the surveillance
method used to assess outcomes in each trial, categorizing it as ac-
tive (staff entry into the field to identify cases or establishment of
additional study clinics), intermediate (reliance on existing clinics
and encouragement to evaluate participants for typhoid fever) or
passive (no increase in surveillance). We also recorded the unit
of randomization and indicated whether trials were adjusted for
cluster-randomization in the analysis.
For dichotomous outcome measures, we recorded the number of
participants experiencing the event and the number analyzed in
each treatment group. For trials randomly assigned using clusters
(cluster-RCTs) we extracted cluster-adjusted risk ratios when avail-
able; we also recorded the number of clusters in the trial, the aver-
age size of clusters and the unit of randomization (eg, household
or institution). The statistical methods used to analyze the trial
results were documented, along with details describing whether
these methods were adjusted for clustering or for other co-vari-
ables.
Assessment of risk of bias in included studies
We (E Anwar and E Goldberg) independently assessed the risk of
bias in included trials; in cases of disagreement, we consulted a
third review author (M Paul). We took an individual component
approach to quality assessment by using five variables: generation
of allocation sequence; allocation concealment; blinding of par-
ticipants and investigators; inclusion of all randomly assigned par-
ticipants in the analysis; and reporting of all stated outcomes. We
categorized generation of the allocation sequence and allocation
concealment as adequate, unclear, or inadequate by using the ap-
proach described in Jüni 2001. We recorded whether trials used
single, double or no blinding, and whether all randomly assigned
participants were included in the results. We classified inclusion
of all randomly assigned participants in the analysis as adequate if
at least 90% and as inadequate if less than 90%.
Data synthesis
If a single reference included more than one trial, we labelled the
trials separately using a letter (eg, Wang 1997a CHN and Wang
1997b CHN); if a single trial compared several vaccine armswith a
control arm,we labelled the arms separately using a romannumeral
(eg, Black 1990i CHL andBlack 1990ii CHL). To avoid including
data for controls more than once in the same comparison, we
divided the placebo group into equal parts while assuming equal
incidence in these groups.
We combined dichotomous data from trials that randomly as-
signed individuals by using risk ratios (RRs) and presented them
with 95% confidence intervals (CIs). We interpreted the results as
efficacy, defined as 1-RR and expressed as a percentage.We pooled
cluster-RCT data that had been adjusted for clustering with data
from trials that randomly assigned individuals (individual-RCTs)
using the generic inverse variance method. When the results of a
cluster-RCT had not been adjusted for clustering, we did not pool
the data but presented the data in the additional table section.
We explored the following potential sources of heterogeneity in
subgroup analyses: number of doses; length of follow-up; and vac-
cine type (Ty21a vaccine, Vi polysaccharide vaccine or Vi-rEPA)
and age (if data were available). We rounded to the nearest year
when trials included follow-up for only part of a year.
We calculated cumulative three-year efficacy, defined as efficacy
for the entire three-year period, by vaccine type, as above. We also
recorded cumulative data on vaccine efficacy for longer than three
years of follow-up, if available. We analyzed efficacy per year and
cumulative efficacy, as they provide different information. Analyses
per year showwhether the effect of the vaccine decreases over time,
and cumulative efficacy demonstrates efficacy overall, for a given
period, regardless of whether changes over time occurred within
this period.
We extracted data on adverse events from trials comparing a ty-
phoid fever vaccine with placebo, and from trials comparing a ty-
phoid fever vaccine with a different typhoid fever vaccine. When
the occurrence of adverse events was reported after each of several
doses, we extracted only the occurrence after the first dose. Simi-
larly, when reports provided estimates of the incidence of adverse
events for different time points after vaccination, we presented the
data corresponding to 24 hours after vaccination.
We assessed heterogeneity by inspecting the forest plots to detect
overlapping confidence intervals and by applying the Chi2 test
with a P-value of 0.10 indicating statistical significance and the
I2 statistic with a value of 50% used to denote moderate levels
of heterogeneity. The random-effects model was used throughout
the review.
We calculated number needed to treat for an additional benefi-
cial outcome (NNTB) (1/reduction in risk of typhoid fever at-
tributable to vaccination) for each type of vaccine based on the
cumulative 2.5- to 3-year point estimate and the incidence of ty-
phoid fever in control groups of trials assessing the given vaccina-
tion.
Quality of evidence
The quality of evidence across each outcome measure was assessed
using the GRADE approach. The quality rating across studies has
one of four levels: high, moderate, low or very low. Randomized
trials are initially categorized as high quality but can be down-
graded after assessment of five criteria: risk of bias, consistency,
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directness, imprecision and publication bias (Guyatt 2008). The
main results of the review and the quality assessments are displayed
in the ’Summary of findings’ tables.
R E S U L T S
Description of studies
Results of the search
Four hundred forty-two potentially relevant publications were
identified, and after screening, 80 publications were retrieved for
full-text inspection. See Figure 1 for the study flow diagram. Five
trials were identified as currently ongoing (see Characteristics of
ongoing studies).
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Figure 1. Study flow diagram.
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Included studies
Altogether, 26 publications (18 trials-12 individual-RCTs and
six cluster-RCTs) met the inclusion criteria (see details in
Characteristics of included studies table).
This review update includes four new trials that were not included
in the previous review: three of the new trials evaluated the Vi
polysaccharide vaccine, two trials reported on efficacy and adverse
events (Khan 2012 PAK; Sur 2009 IND ) and one trial reported
adverse events only (Zhou 2007 CHN). One trial evaluated ad-
verse events associated with the Vi-rEPA vaccine (Thiem 2011
VNM). All of the newly included trials were conducted in Asia.
Excluded studies
A total of 50 publications (43 trials) were excluded from the review.
For details of excluded trials and reasons for their exclusion, see
the Characteristics of excluded studies table.
Outcomes
Data on the primary outcome, cases of typhoid fever, were derived
from 12 trials:
• Five trials of Ty21a (Black 1990i CHL; Black 1990ii CHL;
Levine 1987i CHL; Levine 1987ii CHL; Levine 1987iii CHL;
Levine 1987iv CHL; Levine 1990i CHL; Levine 1990ii CHL;
Simanjuntak 1991i IDN; Simanjuntak 1991ii IDN; Wahdan
1980a EGY);
• Six trials of Vi polysaccharide (Acharya 1987 NPL; Khan
2012 PAK; Klugman 1987 ZAF; Sur 2009 IND; Wang 1997a
CHN; Yang 2001 CHN); and
• One Vi-rEPA trial (Lin 2001 VNM).
Data on the secondary outcome, adverse events, were taken from
11 trials:
• Three trials of Ty21a (Levine 1986i CHL; Levine 1986ii
CHL; Olanratmanee 1992 THA; Simanjuntak 1991ii IDN);
• Six trials of Vi polysaccharide (Keitel 1994 USA; Khan
2012 PAK; Sur 2009 IND; Wang 1997a CHN; Yang 2001
CHN; Zhou 2007 CHN); and
• Two trials of Vi-rEPA (Lin 2001 VNM; Thiem 2011
VNM).
One additional trial assessed the Ty21a vaccine and reported on
adverse events but did not provide the number of participants per
study arm (Cryz 1993 THA); therefore results of this trial were
not included in the meta-analysis.
All efficacy trials and all but one adverse event trial (Keitel 1994
USA) were performed in countries in which typhoid fever is en-
demic; Chile four trials, China three trials, Vietnam two trials,
Thailand two trials, Egypt one trial, India one trial, Indonesia
one trial, Nepal one trial, Pakistan one trial and South Africa one
trial. None of the trials evaluated vaccine efficacy in travellers from
developed countries. None of the trials compared the efficacy of
different types of typhoid vaccines.
Risk of bias in included studies
See Figure 2 for a summary of the assessment and the ’
Characteristics of included studies’ for further details on the rea-
sons for review authors’ judgements.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Efficacy trials
Five of the 12 efficacy trials reported adequate randomization pro-
cedures (Khan 2012 PAK; Simanjuntak 1991i IDN; Simanjuntak
1991ii IDN; Sur 2009 IND; Wang 1997a CHN; Wang 1997b
CHN; Yang 2001 CHN). In the other seven trials, insufficient
information was supplied to permit judgement. All but one trial
(Klugman 1987 ZAF) used adequate methods to conceal alloca-
tion.
Adverse event trials
Six of the 12 trials looking at adverse events reported adequate
randomization procedures (Khan 2012 PAK; Simanjuntak 1991i
IDN; Simanjuntak 1991ii IDN; Sur 2009 IND; Wang 1997a
CHN;Wang 1997b CHN; Yang 2001 CHN; Zhou 2007 CHN).
Six of 12 trials used adequate methods to conceal allocation (
Khan 2012 PAK; Lin 2001 VNM; Simanjuntak 1991i IDN;
Simanjuntak 1991ii IDN; Sur 2009 IND; Wang 1997a CHN;
Wang 1997b CHN; Yang 2001 CHN), but in the other trials,
insufficient information was supplied to permit judgement.
Blinding
Efficacy trials
All but two trials used double blinding. Two cluster-randomized
trials (Khan 2012 PAK; Sur 2009 IND) could not guarantee blind-
ing of researchers or participants, as they used vaccines that were
packaged differently and therefore did not look identical. How-
ever, both trials tried to minimize this effect by assigning each vac-
cination team to only one vaccine, identifying the vaccines only
by code and not informing local research staff members or partic-
ipants of the assignment of the code or the vaccine.
Adverse event trials
All but three trials used double blinding. Two trials (Khan 2012
PAK; Sur 2009 IND) used vaccines that did not look identical, as
outlined above, and one trial (Thiem 2011 VNM) did not state
whether blinding had taken place.
Incomplete outcome data
Efficacy trials
Nine of 12 trials were assessed as adequate in terms of including
all randomly assigned participants in the analysis. In three trials
(Black 1990i CHL;Black 1990ii CHL; Levine 1987i CHL; Levine
1987ii CHL; Levine 1987iii CHL; Levine 1987iv CHL; Levine
1990i CHL; Levine 1990ii CHL), no reasons for missing data
were provided.
Adverse event trials
Ten of 12 trails were assessed as adequate in terms of including
all randomly assigned participants in the analysis or providing
reasons for missing outcome data. Two trials were unclear on this
issue (Cryz 1993 THA; Levine 1986i CHL; Levine 1986ii CHL).
One additional trial assessed the Ty21a vaccine and reported on
adverse events but did not provide the number of participants per
study arm (Cryz 1993 THA); therefore results of this trial were
not included in the meta-analysis.
Selective reporting
Efficacy trials
All 12 trials reported on expected outcomes.
Adverse event trials
All 12 trials reported on expected outcomes.
Other potential sources of bias
Efficacy trials
Four of the six cluster-RCTs provided data on the efficacy of the
Ty21a vaccine (Black 1990i CHL;; Levine 1987i CHL; Levine
1990i CHL; ; Wahdan 1980a EGY). However, these four cluster-
RCTs, all of which randomly assigned by classroom, did not adjust
for clustering in their results; therefore we could not include their
results in the meta-analyses.
The two remaining cluster-RCTs included within the review pro-
vided data on the efficacy of the Vi polysaccharide vaccine (Khan
2012 PAK; Sur 2009 IND). Both of these trials randomly assigned
by geographic clusters. Study authors were contacted to gather
unpublished cluster-adjusted data for inclusion within the meta-
analysis.
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Adverse event trials
Two cluster-RCTs provided data on adverse events associated with
the Vi polysaccharide vaccine (Khan 2012 PAK; Sur 2009 IND);
however, these cluster-RCTs did not adjust for clustering in their
results and therefore were not included in the meta-analyses.
Effects of interventions
See: Summary of findings for the main comparison
Ty21a vaccine (three doses) compared with control; efficacy
for preventing typhoid fever; Summary of findings 2 Vi
polysaccharide vaccine (one dose) compared with control; efficacy
for preventing typhoid fever; Summary of findings 3 Vi-rEPA
vaccine (two doses) compared with control; efficacy for preventing
typhoid fever
TY21a vaccine
Efficacy
This vaccine has been evaluated in one three-arm RCT (
Simanjuntak 1991i IDN) and in four cluster-RCTs. The cluster-
RCTs did not adjust analyses for the effect of clustering; therefore
any protective effect is likely overestimated (Black 1990ii CHL;
Levine 1987i CHL; Levine 1987ii CHL; Levine 1987iii CHL;
Levine 1987iv CHL; Wahdan 1980a EGY, Levine 1990i CHL.
Levine 1990ii CHL). We could not include these studies in the
meta-analysis.
A three-dose schedule ofTy21a vaccine provided vaccine efficacy of
35% at Year 1 (95% CI 8% to 54%; 20,543 participants; Analysis
1.1), 58% at Year 2 (95% CI 40% to 71%; 20,543 participants;
Analysis 1.2) and 46% at Year 3, although this finding was not
statistically significant (95%CI -6% to 72%; 20,543 participants;
Analysis 1.3). The cumulative efficacy of the Ty21a vaccine over
2.5 to 3 years was 48% (95%CI 34% to 58%; 20,543 participants;
Analysis 1.4). A comparison of cumulative efficacy between the
liquid formulation and the enteric capsules showed no statistically
significant difference (10,215 participants; Simanjuntak 1991ii
IDN; Analysis 2.1).
Results of the four unadjusted cluster-RCTs for the three-dose
schedule of Ty21a vaccine liquid formulation or enteric capsules
were similar to the individual-RCT results and are presented in
Table 1. Cumulative efficacy of the three-dose schedule of Ty21a
vaccine for over three years is available from two of the unadjusted
cluster-RCTs (Levine 1987ii CHL; Levine 1990i CHL). Cumu-
lative efficacy was 79% at five years (95% CI 65% to 87%; Table
2) and 62% at seven years (95% CI 48% to 73%; Table 2).
We were unable to conduct subgroup analysis by age, as trials
evaluating the efficacy of the Ty21a vaccine did not stratify results
by age.
Adverse events
None of the individual- or cluster-randomized trials report any
serious adverse events (leading to death, requiring inpatient hos-
pitalization or prolonged existing hospitalization, life threatening
or resulting in persistent or significant disability or incapacity).
Compared with placebo, the Ty21a vaccine (both preparations)
was not associated with an increased rate of vomiting (two trials/
four arms, 2066 participants; Analysis 3.2), diarrhoea (two trials/
four arms, 2066 participants; Analysis 3.3), nausea or abdomi-
nal pain (two trials/four arms, 2066 participants; Analysis 3.4),
headache (one trial/two arms, 1190 participants; Analysis 3.5) or
rash (one trial/two arms, 1190 participants; Analysis 3.6) com-
pared with control. However, fever (RR 1.84, 95% CI 1.02 to
3.05; two trials/four arms, 2066 participants) was more common
after vaccine delivery. A pooled analysis of two individual-RCTs
showed a marginal increase in risk of any mild adverse events (RR
1.67, 95% CI 1.03 to 2.72; two trials/three arms, 1360 partici-
pants; Analysis 3.7).
Vi polysaccharide vaccine
Efficacy
The efficacy of this vaccine has been evaluated in four individu-
ally randomized RCTs (Acharya 1987 NPL; Klugman 1987 ZAF;
Wang 1997a CHN; Yang 2001 CHN) and in two cluster-RCTs
(Khan 2012 PAK; Sur 2009 IND). We contacted the cluster-ran-
domized study authors to obtain unpublished cluster-adjusted re-
sults for efficacy at Year 2 following vaccination. Wewere therefore
able to pool the results from the individually randomized RCTs
and the cluster-adjusted RCTs using the generic inverse variance
method.
The efficacy of the Vi polysaccharide vaccine was 69% at Year 1
(95% CI 63% to 74%; three trials, 99,797 participants; Analysis
4.1), 59% at Year 2 (95% CI 45% to 69%; four trials, 194,969
participants; Analysis 4.1) and 50% at Year 3 based on a single
trial (95% CI 22% to 68%, 11,384 participants; Analysis 4.1).
Cumulative efficacy at 2.5 to 3 years, based on the same single trial
(Klugman 1987 ZAF), was 55% (95% CI 30% to 70%; 11,384
participants; Analysis 4.2).
Two of the trials used the Widal test (as well as a positive culture)
to detect cases of typhoid fever (Wang 1997a CHN; Yang 2001
CHN). Results of the Widal test were not included in the meta-
analysis. Both trials followed participants for six years, and their
combined results demonstrated that protection was significant in
each of the first two years but not in Years 3 to 6 separately. Three-
year cumulative efficacy was 69% (95% CI 50% to 81%), and
combined efficacy for Years 4 through 6 was 11% (95% CI -76%
to 55%) (analyses not shown).
Three of the trials conducted subgroup analysis by age: one in-
dividual-RCT (Yang 2001 CHN) and two cluster-RCTs (Khan
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2012 PAK; Sur 2009 IND). However, the individual-RCT (Yang
2001 CHN) included very small numbers in each age group; the
two cluster-RCTs (Khan 2012 PAK; Sur 2009 IND) did not ad-
just for clustering and presented their results in the form of haz-
ard ratios rather than risk ratios (with effectiveness of vaccination
estimated as [1-hazard ratio] × 100%). We were therefore unable
to conduct subgroup analysis by age. Unadjusted results by age
from the two cluster-RCTs are presented in Table 3. The cluster-
randomized trial conducted in India (Sur 2009 IND) found that
compared with control, the Vi polysaccharide vaccine provided
significant protection for children 2 to 5 years of age two years
after vaccination (efficacy 59%, 95% CI 18% to 79%). However,
contrary to these results, the cluster-randomized trial conducted in
Pakistan (Khan 2012 PAK) showed no protection among children
between two and five years of age compared with placebo at two
years after vaccination (efficacy -30%, 95% CI -183% to 40%).
Adverse events
No trials reported any serious adverse events (leading to death,
requiring inpatient hospitalization or prolonged existing hospital-
ization, life threatening, or resulting in persistent or significant
disability or incapacity).
Overall, no statistically significant difference was noted between
vaccine and placebo in the incidence rate of fever (four tri-
als, 133,038 participants; Analysis 5.1) or erythema (three trials,
132,261 participants; Analysis 5.2). However, swelling (RR 6.06,
95% CI 1.07 to 34.22; three trials, 1767 participants; Analysis
5.3) and pain at the injection site (RR 7.98, 95%CI 3.69 to 17.24;
one trial, 667 participants; Analysis 5.4) were more common after
delivery of the Vi polysaccharide vaccine.
Two cluster-RCTs presented data on adverse events for a subgroup
of participants. These data were not adjusted for clustering and
therefore could not be included within the meta-analysis; results
were similar to the individual-RCT results, with erythema and
pain at the injection site reported more commonly in the vaccine
group (Table 4).
Vi-rEPA vaccine
Efficacy
The efficacy of this vaccine has been evaluated by one trial in
children 2 to 5 years of age conducted in Vietnam (Lin 2001
VNM). The efficacy of the Vi-rEPA vaccine was 94% at Year 1
(95%CI 75% to 99%; 12,008 participants; Analysis 6.1) and 87%
at Year 2 (95%CI 56% to 96%; 12,008 participants; Analysis 6.1).
The cumulative efficacy of the Vi-rEPA vaccine after 3.8 years was
89% (95% CI 76% to 97%; 12,008 participants).
The efficacy of this vaccine has been evaluated only in children 2
to 5 years of age; we were therefore unable to conduct subgroup
analysis by age.
Adverse events
No trials reported any serious adverse events (leading to death,
requiring inpatient hospitalization or prolonged existing hospi-
talization, life threatening or resulting in persistent or significant
disability or incapacity).
Two trials evaluated adverse events associated with this vaccine
(Lin 2001 VNM; Thiem 2011 VNM). Investigators reported no
statistically significant difference between the vaccine and placebo
for the incidence of fever after doses 1 and 2 (Analysis 7.1; Analysis
7.2), erythema after doses 1 and 2 (Analysis 7.3; Analysis 7.4) or
swelling after doses 1 and 2 (Analysis 7.5; Analysis 7.6).
Heterogeneity
In most comparisons that included several trials, the degree of
heterogeneity was not substantial (ie, I2 < 50% and Chi2 test with
P value > 0.10). However, because of the limited number of trials
included in each comparison, we were unable to conclude why
a greater degree of heterogeneity in trial results was apparent in
some comparisons.
Sensitivity analyses
We performed sensitivity analyses for trials for which the con-
trol arm was split in the main analyses and found that the results
were not altered (analyses not shown). As most comparisons in-
cluded few trials, we could not perform sensitivity analyses by trial
methodological quality (risk of bias). No difference was noted in
adverse event results from trials that did and did not evaluate ef-
ficacy, although no formal testing was undertaken.
Number needed to treat for an additional beneficial
outcome (NNTB) to prevent one case of typhoid
fever
Ty21a vaccine
Based on the results of one individual-RCT, the liquid formula-
tion of the Ty21a vaccine had a three-year cumulative protective
efficacy of 53% (95% CI 34% to 67%; Simanjuntak 1991i IDN;
Analysis 1.4). The incidence rate in the control group was 2021/
100,000 with a corresponding NNTB of 93 (95% CI 74 to 145).
The enteric capsule formulation of the Ty21a vaccine had three-
year cumulative protective efficacy of 42% (95% CI 21% to 58%;
Simanjuntak 1991ii IDN; Analysis 1.4). The incidence in the con-
trol group was 2031/100,000, and the corresponding NNTB was
237 (95% CI 86 to 119)
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Vi polysaccharide vaccine
The Vi polysaccharide vaccine has a 2.5- to 3-year cumulative
protective efficacy of 55% (95% CI 30% to 70%; Klugman 1987
ZAF; Analysis 3.2) with an incidence rate of 1160/100,000. From
these data, we estimated the NNTB to be 192 (95% CI 124 to
288).
16Vaccines for preventing typhoid fever (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Vi polysaccharide vaccine (1 dose) compared with control; efficacy for preventing typhoid fever
Patient or population: adults and children of 2 years of age and older
Settings: any
Intervention: Vi polysaccharide vaccine (1 dose)
Comparison: control; efficacy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control; efficacy Vi polysaccharide vac-
cine (1 dose)
Incidence of typhoid
fever-Year 1
Blood culture
Moderate1 RR 0.31
(0.26 to 0.37)
99,797
(3 studies)
⊕⊕⊕⊕
high2,3,4,5
4 per 10,000 1.2 per 10,000
(1.0 to 1.5)
High1
51 per 10,000 15.8 per 10,000
(13.3 to 18.9)
Incidence of typhoid
fever-Year 2
Moderate1 RR 0.41
(0.31 to 0.55)
194,969
(4 studies)
⊕⊕⊕©
moderate2,6,7,5
4 per 10,000 1.6 per 10,000
(1.2 to 2.2)
High1
51 per 10,000 20.9 per 10,000
(15.8 to 28.1)
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Serious adverse events See comment See comment Not estimable 133,240
(4 studies)
See comment No serious adverse
events were reported
Fever 5 per 1000 5 per 1000
(3 to 8)
RR 0.93
(0.57 to 1.53)
133,038
(4 studies)
⊕⊕⊕©
moderate2,3,8,9
Erythema 5 per 1000 6 per 1000
(2 to 22)
RR 1.15
(0.33 to 4.03)
132,261
(3 studies)
⊕⊕⊕©
low2,10,9
*The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence:
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1The incidence of typhoid in a medium-risk setting is taken from the control group in a study from china (Yang 2001 CHN).The incidence
of typhoid in a high-risk setting is taken from a study in India (Sur 2009 IND). This is consistent with the incidence levels described
by a global epidemiological study (Crump 2004).
2No serious risk of bias detected.
3No serious inconsistency: The result was consistent across all three trials (I2 = 0%).
4No serious indirectness: The vaccine has been evaluated in trials from Nepal, South Africa and China. Of note, none of the trials were
conducted in travellers from nonendemic settings, and all three trials excluded children younger than 2 years of age and pregnant women.
5No serious imprecision: The result is statistically significant with a narrow 95% CI. The meta-analysis is adequately powered to detect
this effect.
6Downgraded by 1 for inconsistency: The magnitude of the protective effect varied between trials from 34% to 69% (I2 = 72%). The
reasons for this are not clear; one potential factor may be the different age groups included in the trials, with the trial by (Khan 2012
PAK) suggesting lower protective effect in children <5 years of age.
7No serious indirectness: The vaccine has been evaluated in trials from endemic settings (India, Pakistan, China and South Africa).
8No serious indirectness: The vaccine has been evaluated in trials from endemic settings (China) and in one trial conducted in a
nonendemic setting (USA).
9Downgraded by 1 for serious imprecision: The result is not statistically significant.
10Downgraded by 1 for inconsistency (I2 = 63%).
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Vi-rEPA vaccine (2 doses) compared with control; efficacy for preventing typhoid fever
Patient or population: adults and children of 2 years of age and older
Settings: any
Intervention: Vi-rEPA vaccine (2 doses)
Comparison: control; efficacy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control; efficacy Vi-rEPA vaccine (2
doses)
Incidence of typhoid
fever-Year 1
Follow-up: 1 year
Moderate1 RR 0.06
(0.01 to 0.25)
12,008
(1 study)
⊕⊕⊕©
moderate2,3
4 per 10,000 024 per 10,000
(0.04 to 1)
High1
59 per 10,000 3.5 per 10,000
(0.6 to 14.8)
Incidence of typhoid
fever-Year 2
Moderate1 RR 0.13
(0.04 to 0.44)
12,008
(1 study)
⊕⊕⊕©
moderate3
4 per 10,000 0.52 per 10,000
(0.16 to 1.8)
High1
59 per 10,000 7.7 per 10,000
(2.4 to 26.0)
Serious adverse events See comment See comment Not estimable 12,209
(2 studies)
See comment No serious adverse
events were reported1
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Fever after Vi-rEPA
(dose1)
9 per 1000 14 per 1000
(5 to 39)
RR 1.55
(0.57 to 4.23)
12,209
(2 studies)
⊕⊕©©
low4,5
Erythema after Vi-rEPA
(dose 1)
0 per 1000 0 per 1000
(0 to 5)
RR 3.03
(0.32 to 28.64)
12,209
(2 studies)
⊕⊕⊕©
moderate5
Swelling at injection site
after Vi-rEPA (dose 1)
0 per 1000 0 per 1000
(0 to 2)
RR 1.01
(0.15 to 7.03)
12,209
(2 studies)
⊕⊕⊕©
moderate5
*The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence:
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1The incidence of typhoid in a medium -risk setting is taken from the control group in a study from china (Yang 2001 CHN).The incidence
of typhoid in a high-risk setting is taken from a study in India (Sur 2009 IND). This is consistent with the incidence levels described
by a global epidemiological study (Crump 2004).
2No serious risk of bias detected.
3Downgraded by 1 for indirectness: The vaccine has been evaluated by only one trial in children 2 to 5 years of age in a high-incidence
setting (Vietnam).
4Downgraded by 1 for serious inconsistency: I2 = 89%.
5Downgraded by 1 for serious imprecision: The result is not statistically significant.
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D I S C U S S I O N
Summary of main results
Ty21a vaccine (three doses)
A three-dose schedule of Ty21a vaccine probably prevents around
one-third to one-half of typhoid cases during the first two years
after vaccination (Year 1: 35%, 95% CI 8% to 54%; Year 2: 58%,
95% CI 40% to 71%; one trial, 20,543 participants; moderate
quality evidence). These data are taken from a single trial conducted
in Indonesia in the 1980s. No statistically significant benefit was
seen in the third year after vaccination. Four additional cluster-
RCTs have been conducted, but the authors did not adjust for
clustering.
Compared with placebo, this vaccine was not associated withmore
participants with vomiting, diarrhoea, nausea or abdominal pain
(four trials, 2066participants;moderate quality evidence) headache,
or rash (two trials, 1190 participants; moderate quality evidence);
however, fever (four trials, 2066 participants; moderate quality ev-
idence) was more common in the vaccine group.
Vi polysaccharide vaccine (one dose)
A single dose of Vi polysaccharide vaccine prevents around two-
thirds of typhoid cases in the first year after vaccination (Year
1: 69%, 95% CI 63% to 74%; three trials, 99,979 participants;
high quality evidence). In Year 2, trial results were more variable,
with the vaccine probably preventing between 45% and 69% of
typhoid cases (Year 2: 59%, 95%CI 45% to 69%; 4 trials, 194,969
participants;moderate quality evidence). The three-year cumulative
efficacy of the vaccine is probably around 55% (95% CI 30%
to 70%; 11,384 participants, one trial; moderate quality evidence).
These datawere taken from a single trial conducted in South Africa
in the 1980s.
Compared with placebo, this vaccine was not associated with an
increased rate of fever (four trials, 133,038 participants; moderate
quality evidence) or erythema (three trials, 132,261 participants;
low quality evidence); however, swelling (three trials, 1767 partici-
pants;moderate quality evidence) and pain at the injection site (one
trial, 667 participants; moderate quality evidence) were more com-
mon in the vaccine group.
Vi-rEPA vaccine (two doses)
Administration of two doses of the Vi-rEPA vaccine probably pre-
vents between 50% and 96% of typhoid cases during the first two
years after vaccination (Year 1: 94%, 95% CI 75% to 99%; Year 2:
87%, 95% CI 56% to 96%, one trial, 12,008 participants; mod-
erate quality evidence). These data are taken from a single trial with
children two to five years of age conducted in Vietnam.
Compared with placebo, the first and second doses of this vaccine
were not associated with increased risk of adverse events. The first
dose of this vaccinewas not associatedwith fever (two trials, 12,209
participants; low quality evidence), erythema (two trials, 12,209
participants; moderate quality evidence) or swelling at the injection
site (two trials, 12,209 participants; moderatequality evidence).
The second dose of this vaccine was not associated with fever (two
trials, 11,286 participants; low quality evidence),erythema (two tri-
als, 11,286 participants; moderate quality evidence)and swelling at
the injection site (two trials, 11,286 participants; moderate quality
evidence).
Overall completeness and applicability of
evidence
In the absence of trials directly comparing different types of ty-
phoid vaccines, we provide an indirect means of comparing the
efficacy of different vaccines. The cumulative efficacy at 2.5 to 3
years for the Ty21a vaccine (3 doses) and the Vi polysaccharide
vaccine was 48% (95% CI 34% to 58%) and 55% (95% CI 30%
to 70%), respectively. The cumulative efficacy of the Vi-rEPA vac-
cine at 3.8 years was higher (89%, 95% CI 76% to 97%), but
this vaccine is unlicensed. Adverse events were mild in nature and,
for the most, were not significantly different between vaccine and
placebo groups.
Ty21a vaccine (three doses)
Although the efficacy of the Ty21a vaccine was evaluated in five
separate trials, four of thesewere cluster-RCTs that did not account
for this design in the analysis and therefore were not included in
the meta-analyses. In general, the cluster-RCTs suggested greater
efficacy of the Ty21a vaccine, as would be expected in trials that do
not adjust appropriately for the effect of clustering. The data for
the efficacy of this vaccine therefore were derived from one three-
arm individually randomized RCT conducted in Indonesia in the
1980s. Further evidence from other settings would be valuable in
proving the generalizability of these findings.
None of the studies presented subgroup data by age. Therefore, we
cannot report on efficacy of this vaccine in different age groups.
Vi polysaccharide vaccine (one dose)
Evidence available from four trials conducted in four different
settings (two high-incidence settings: India and Pakistan; and
two medium-incidence settings: China and South Africa) demon-
strates that the Vi polysaccharide vaccine is efficacious for the first
two years after vaccination.One trial fromSouth Africa conducted
in the 1980s provided efficacy data at three years.
Two recent cluster-RCTs presented unadjusted efficacy results
stratified by age with contrasting results (presented in Table 3).
The cluster-RCT conducted in India (Sur 2009 IND) found that
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compared with control, the ViPS vaccine provided significant pro-
tection in children 2 to 5 years of age two years after vaccina-
tion. However, contrary to these results, the cluster-RCT con-
ducted in Pakistan (Khan 2012 PAK) did not show any protec-
tion among children between two and five years of age compared
with placebo. The reasons for the difference in effectiveness by
age are unclear. The two trials differed in methodology, with the
trial in India taking a mass vaccination approach (vaccinating the
entire population) and the trial in Pakistan targeting only chil-
dren. The trial conducted in India, which took a mass vaccina-
tion approach, demonstrated indirect protection (herd immunity)
within the population under study; this was not seen in the trial in
Pakistan, in which only children were vaccinated. It may be that
this indirect protection led to reduced overall transmission within
the intervention clusters and a reduced incidence of typhoid fever
among young children compared with control clusters observed
within the Indian trial.
Vi-rEPA vaccine (two doses)
Evidence of the efficacy of this vaccine is available from a single
trial conducted in Vietnam (Lin 2001 VNM). This single study
assessed efficacy of the vaccine only in children two to five years of
age; therefore vaccine efficacy in different settings and age groups
is unknown.
Quality of the evidence
We assessed the quality of evidence provided by the randomized
studies using the GRADE approach; these assessments are pre-
sented in Summary of findings for themain comparison, Summary
of findings 2 and Summary of findings 3.
Ty21a vaccine (three doses)
Evidence obtained for the protective efficacy of the Ty21a vaccine
was judged to be of moderate quality. The quality was downgraded
for indirectness-this vaccine has been evaluated in only one setting
(Indonesia), and studies fromelsewherewould be important before
this result can be widely generalized.
Vi polysaccharide vaccine (one dose)
Evidence obtained for the protective efficacy of the Vi polysac-
charide vaccine was judged to be of high quality at Year 1 and of
moderate quality at Year 2. At Year 2, the quality was downgraded
for inconsistency-the magnitude of the protective effect varied be-
tween trials from 34% to 69% (I2 = 72%). The reason for this may
be the different efficacy of the vaccine within different age groups,
with one cluster trial (Khan 2012 PAK) finding that compared
with control, the vaccine did not provide significant protection to
children between 2 and 5 years of age.
Vi-rEPA vaccine (two doses)
Evidence obtained for the protective efficacy of the Vi-rEPA vac-
cine was judged to be of moderate quality. The quality was down-
graded for indirectness-the vaccine has been evaluated only in chil-
dren 2 to 5 years of age in one high-incidence setting (Vietnam),
and studies of participants of different ages conducted elsewhere
would be important before this result can be widely generalized.
The quality of the evidence obtained for the adverse event of fever
was downgraded for inconsistency (I2 = 89% Year 1; I2 = 85%
Year 2). The reason for this heterogeneity is unclear, as both trials
were conducted among children younger than 5 years in Vietnam.
Further investigation of the potential adverse events of this vaccine
is warranted.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the available evidence, the currently licensed Ty21a and
Vi polysaccharide vaccines are efficacious and safe public health
measures for preventing typhoid fever. Factors such as costs, avail-
ability and convenience of administration may determine which
vaccine is chosen for use.
Implications for research
An effective typhoid vaccine is needed for young children. Neither
the Vi polysaccharide vaccine nor the Ty21a vaccine is licensed
for children younger than 2 years of age. Given the finding that
typhoid fever affects infants (Saha 2001; Sinha 1999), develop-
ment of a vaccine suitable for this age group is required. Future
trials should be sufficiently powered to present results stratified
by age group. This would mean that vaccine efficacy in different
groups could be analyzed and would ensure that vaccine delivery
can be targeted appropriately (eg, via a school-based programme
or through the expanded programme of vaccination (EPI)).
None of the included trials compared different types of vaccines
used to prevent typhoid fever. Such future comparisons may be
helpful in allowing direct conclusions regarding the relative effi-
cacy of the vaccines, although such evidence would not necessarily
promote the introduction of vaccines against typhoid fever to new
settings and would require substantial resources.
Future trials should conduct analyses suited to their design; cluster-
randomization should be accounted for in sample size calculations
and in analyses of results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Acharya 1987 NPL
Methods Design: individual-RCT
Active surveillance for efficacy (health workers visited vaccinees every 2 days; in case of
a fever lasting longer than 3 days, a blood sample was taken) and adverse events (health
workers examined vaccinees on days 1 to 3 post-vaccination)
Participants Number: 6907
Inclusion criteria: age 5 to 44 years
Exclusion criteria: children age < 2 years; fever or acute illness; pregnancy
Interventions 1. Capsular polysaccharide of S. typhi, Vi: 25 µg Vi in 0.5 mL; 3457 participants
2. Pneumococcal vaccine: 25 µg; 3450 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Adverse events
Notes Location: 5 villages near Kathmandu, Nepal
Socioeconomic description: rural, low income
Setting: home
Date: 1986 to 1988
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized, random arrangement of sy-
ringes in packages of 10. Insufficient infor-
mation about the sequence generation pro-
cess provided to permit judgement
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identi-
cal appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of randomized assigned partici-
pants in analysis: 100%
Selective reporting (reporting bias) Low risk All expected outcomes reported on
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Acharya 1987 NPL (Continued)
Other bias Low risk None
Black 1990i CHL
Methods Design: cluster (classroom)-RCT
Intermediate surveillance for efficacy: enteric fever and isolation of S. typhi from blood
or bone marrow in clinics and local hospital during the study (5-year follow-up)
Participants Number: 54,925 participants
Number of classrooms: 3655
Inclusion criteria: age 5 to 22 years
Exclusion criteria: no details
Interventions 1. Lyophilized attenuated S. typhi strain Ty21a: enteric-coated capsule containing 2-5 ×
109 viable Ty21a; 27,620 participants
2. Placebo: in enteric-coated capsule; 27,305 participants
Route and schedule: oral; 2 doses, 1 week apart
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia or in bone marrow)
Notes Location: northern area of Santiago, Chile
Socioeconomic description: no details
Setting: school
Date: 1982 to 1987
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Low risk Allocation concealment: central (WHO).
Sequentially numbered vaccines of identi-
cal appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of 91,954 participating children, 82,543
received all assigned doses. No reason for
missing data provided
Selective reporting (reporting bias) Low risk All expected outcomes reported on
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Black 1990i CHL (Continued)
Other bias Unclear risk Unclear whether data were adjusted for
clustering
Black 1990ii CHL
Methods See Black 1990i CHL (Black 1990ii CHL is a different arm of the same trial)
Participants Details as for Black 1990i CHL, except number: 54,923
Interventions 1. Lyophilized attenuated S. typhi strain Ty21a: enteric-coated capsule containing 2-5 ×
109 viable Ty21a; 27,618 participants
2. Placebo: in enteric-coated capsule; 27,305 participants
Route and schedule: oral; 1 dose (2nd dose contained placebo in all participants)
Concomitant medication: not specified
Outcomes Details as for Black 1990i CHL
Notes Details as for Black 1990i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Black 1990i CHL
Allocation concealment (selection bias) Low risk Details as for Black 1990i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Black 1990i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Black 1990i CHL
Selective reporting (reporting bias) Low risk Details as for Black 1990i CHL
Other bias Unclear risk Details as for Black 1990i CHL
Cryz 1993 THA
Methods Design: individual-RCT
Participants Number: 634
Inclusion criteria: children 2 to 6 years old with no history of typhoid fever
Exclusion criteria: no details
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Cryz 1993 THA (Continued)
Interventions 1. Ty21a liquid formulation
2. Placebo
Route and schedule: oral solution; 3 doses
Outcomes 1. Adverse events
2. Immunogenicity
Notes Location: Thailand
Socioeconomic description: no details
Date: no details
No demographic details
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the allocation sequence: unclear
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inclusion of randomly assigned participants in analysis: un-
clear
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Other bias Low risk None
Keitel 1994 USA
Methods Design: individual-RCT
Active surveillance for adverse events: local and systemic symptoms before and at 24 and
48 hours after inoculation; fever and symptoms at 6 to 9 hours, days 1, 2, 7, 14 and 28
after inoculation
Participants Number: 323
Inclusion criteria: age 8 to 40 years; healthy; no previous typhoid vaccination
Exclusion criteria: no details
Interventions 1. Capsular polysaccharide of S. typhi, Vi vaccine (freeze-dried preparation and liquid
preparation): 25 µg Vi in 0.5 mL; 237 participants
2. Placebo: 86 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
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Keitel 1994 USA (Continued)
Outcomes 1. Adverse events
2. Immunogenicity
Notes Location: Houston, Texas, USA
Socioeconomic description: urban, high income
Setting: clinic
Date: no information
No demographic information
Results presented jointly for 3 separate trials
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Unclear risk Allocation concealment: unclear
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk none
Khan 2012 PAK
Methods Design: Cluster (geographic clusters)-RCT
Intermediate surveillance for efficacy: Participants were identified through three study
health centres during study period (2 years)
Surveillance for adverse events: All participants were visited 30 minutes after vaccination,
a subgroup of 240 participants were visited 3 days after vaccination and an adverse event
form was completed
Participants 51,965 participants
120 geographic clusters using the Geographic Information System (GIS) imagery (60
clusters in each study arm)
Inclusion criteria: children between the ages of 2 and 16 years
Exclusion criteria: married female children older than 12 years of age were not included
to avoid inadvertent immunization of pregnant women. Recent history of fever
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Khan 2012 PAK (Continued)
Interventions Single-dose capsular polysaccharide of S. typhi, Vi vaccine (dose 25 mcg) or hepatitis A
vaccine (dose 720 IU)
Route and schedule: single intramuscular injection, Vi vaccine or hepatitis A vaccine
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Indirect protection from typhoid fever
3. Adverse events
Notes Location: Karachi, Pakistan
Socioeconomic description: low socioeconomic urban squatter settlements
Date: 2002 and 2007
Setting: vaccination centres and health centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A table of random numbers was used
Allocation concealment (selection bias) Low risk Vaccine identified by code, code assign-
ment held centrally
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigators blinded- vac-
cines identified only by code. One vaccine
administered per cluster
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reason for missing data given (migration,
dying from other causes) and balanced
across groups
Selective reporting (reporting bias) Low risk Study protocol not available but published
study reports on both primary and sec-
ondary outcome
Other bias Low risk No recruitment bias, no baseline imbal-
ance, no loss of clusters, analysis adjusted
for clustering using generalized estimating
equation
Klugman 1987 ZAF
Methods Design: individual-RCT
Active surveillance for efficacy: blood cultures if febrile with no obvious clinical cause
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Klugman 1987 ZAF (Continued)
Participants Number: 11,384
Inclusion criteria: 5 to 15 years
Exclusion criteria: no details
Interventions 1. Capsular polysaccharide of S. typhi, Vi vaccine: 25 µg Vi; 5692 participants
2. Meningococcal vaccine: 25 µg Vi; 5692 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Immunogenicity
Notes Location: eastern Transvaal area of South Africa
Socioeconomic description: no details
Setting: school
Date: 1985 to 1988
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization process unclear
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identi-
cal appearance. Code held by independent
observers
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind. Vaccines identical in appear-
ance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing outcome data. Inclusion of ran-
domized assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Levine 1986i CHL
Methods Design: individual-RCT
Active surveillance for adverse events: no further details
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Levine 1986i CHL (Continued)
Participants Number: 539
Inclusion criteria: adults, no details
Exclusion criteria: no details
Interventions 1. Enteric-coated capsules S. typhi Ty21a vaccine: 172 participants
2. Placebo: 367 participants
Route and schedule: oral capsules; 3 doses
Concomitant medication: not specified
Outcomes 1. Adverse events
Notes Location: Chile
Socioeconomic description: no details
Setting: no details
Date: no details
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Unclear risk Allocation concealment: unclear
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding: double blind (no details)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inclusion of randomly assigned partici-
pants in analysis: unclear
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Levine 1986ii CHL
Methods See Levine 1986i CHL (Levine 1986ii CHL is a different arm of the same trial with
separate placebo group)
Participants Number: 337
Inclusion criteria: children, no details
Exclusion criteria: no details
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Levine 1986ii CHL (Continued)
Interventions 1. S. typhi Ty21a vaccine in milk with NaHCO3S: 172 participants
2. Placebo: 172 participants
Route and schedule: oral capsules; 3 doses
Concomitant medication: not specified
Outcomes Details as for Levine 1986i CHL
Notes Details as for Levine 1986i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1986i CHL
Allocation concealment (selection bias) Unclear risk Details as for Levine 1986i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1986i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1986i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1986i CHL
Other bias Low risk Details as for Levine 1986i CHL
Levine 1987i CHL
Methods Design: cluster (classroom)-RCT
Intermediate surveillance for efficacy: enteric fever and isolation of S. typhi from blood,
bone marrow or bile-stained duodenal fluid in the hospital or in clinics during the trial
(3 years)
Participants Number: 27,074
Number of classrooms: 4312
Inclusion criteria: age 6 to 21 years; parental consent; no further details
Exclusion criteria: no details
Interventions 1. Enteric capsules of S. typhi, Ty21a vaccine: 21,598 participants
2. Placebo: 5476 participants (placebo group divided into 4 equal groups for the com-
parison)
Route and schedule: oral capsules; 3 doses given 21 days apart
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia, in bone marrow or in duodenal fluid)
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Levine 1987i CHL (Continued)
Notes Location: Chile socioeconomic description: no details
Setting: school
Date: 1983 to 1986
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identi-
cal appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inclusion of randomly assigned partici-
pants in analysis: 78% (109,594/141,127)
of enrolled children received 3 doses and
included in results. No reason for missing
data given
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Unclear risk Analysis not adjusted for clustering
Levine 1987ii CHL
Methods See Levine 1987i CHL (Levine 1987ii CHL is a different arm of the same trial)
Details as for Levine 1987i CHL, except blinding: placebo given in a similar regimen,
but not mentioned if identical to gelatin or enteric capsules
Participants Details as for Levine 1987i CHL, except number: 27,647
Interventions 1. Enteric capsules of S. typhi, Ty21a vaccine: 22,170 participants
2. Placebo: 5477 participants (placebo group divided into 4 equal groups for the com-
parison)
Route and schedule: oral capsules; 3 doses given 2 days apart
Concomitant medication: not specified
Outcomes Details as for Levine 1987i CHL
Notes Details as for Levine 1987i CHL
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Levine 1987ii CHL (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1987i CHL
Allocation concealment (selection bias) Low risk Details as for Levine 1987i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1987i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1987i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1987i CHL
Other bias Unclear risk Details as for Levine 1987i CHL
Levine 1987iii CHL
Methods See Levine 1987i CHL (Levine 1987iii CHL is a different arm of the same trial)
Participants Details as for Levine 1987i CHL, except number: 27,017
Interventions Details as for Levine 1987i CHL, except:
1. Gelatin capsules of S. typhi, Ty21a vaccine: 21,541
2. Placebo: 5476 (placebo group divided into 4 equal groups for the comparison)
Outcomes Details as for Levine 1987i CHL
Notes Details as for Levine 1987i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1987i CHL
Allocation concealment (selection bias) Low risk Details as for Levine 1987i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1987i CHL
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Levine 1987iii CHL (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1987i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1987i CHL
Other bias Unclear risk Details as for Levine 1987i CHL
Levine 1987iv CHL
Methods See Levine 1987i CHL (Levine 1987iv CHL is a different arm of the same trial)
Details as for Levine 1987i CHL, except blinding: placebo given in a similar regimen,
but not mentioned whether identical to gelatin or enteric capsules
Participants Details as for Levine 1987i CHL, except number: 27,856
Interventions 1. Gelatin capsules of S. typhi, Ty21a vaccine: 22,379 participants
2. Placebo: 5477 participants (placebo group divided into 4 equal groups for the com-
parison)
Route and schedule: oral capsules; 3 doses given 2 days apart
Concomitant medication: not specified
Outcomes Details as for Levine 1987i CHL
Notes Details as for Levine 1987i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1987i CHL
Allocation concealment (selection bias) Low risk Details as for Levine 1987i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1987i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1987i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1987i CHL
Other bias Unclear risk Details as for Levine 1987i CHL
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Levine 1990i CHL
Methods Design: cluster (classroom)-RCT
Intermediate surveillance for efficacy: enteric fever and isolation of S. typhi from blood,
bone marrow or bile-stained duodenal fluid in the hospital or in clinics during the study
(5 years)
Participants Number: 42,073
Number of classes: 5423
Inclusion criteria: 5 to 19 years old; parental consent; no further details
Exclusion criteria: no details
Interventions 1. Liquid formulation of S. typhi, Ty21a vaccine: 36,623 participants
2. Placebo: 5450 participants
Route and schedule: oral solution; 3 doses given 2 days apart
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia, in bone marrow or in duodenal fluid)
Notes Location: Chile
Socioeconomic description: no details
Setting: school
Date: 1986 to 1991
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identi-
cal appearance. Code kept at WHO
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind. Identical packets and cap-
sules
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inclusion of randomly assigned partici-
pants in analysis: 85% (81,621/95,910
children who received at least 1 dose) re-
ceived all 3 doses and included in results.
No reason for missing data given
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Unclear risk Analysis not adjusted for clustering; how-
ever, authors state, “analysis of cases by class
after three years of follow-up showed no
clustering”
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Levine 1990ii CHL
Methods See Levine 1990i CHL (Levine 1990ii CHL is a different arm of the same trial)
Details as for Levine 1990i CHL, except intermediate surveillance for efficacy for 3 years
Participants Details as for Levine 1990i CHL, except number: 39,548
Interventions Details as for Levine 1990i CHL, except:
1. Enteric capsules of S. typhi, Ty21a vaccine: 34,696 participants
2. Placebo: 4852 participants
Outcomes Details as for Levine 1990i CHL
Notes Details as for Levine 1990i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1990i CHL
Allocation concealment (selection bias) Low risk Details as for Levine 1990i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1990i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1990i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1990i CHL
Other bias Unclear risk Details as for Levine 1990i CHL
Lin 2001 VNM
Methods Design: individual-RCT
Active surveillance for efficacy and adverse events: weekly history; temperature; blood
cultures and serology if febrile during the trial (27 months); review of bacteriological
records in the provincial hospital
Passive surveillance: 19 additional months
Participants Number: 12,008
Inclusion criteria: age 2 to 5 years; no further details
Exclusion criteria: illnesses that required ongoing medical care; fever > 37.5 °C at first
injection
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Lin 2001 VNM (Continued)
Interventions 1. Vi-rEPA vaccine; capsular polysaccharide of S. typhi, Vi, bound to a nontoxic recom-
binant protein that is antigenically identical to Pseudomonas aeruginosa exotoxin A; 22
µg Vi in 0.5 mL; 5991 participants
2. Placebo: 6017 participants
Route and schedule: intramuscular injection; 2 doses, 6 weeks apart
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Adverse events
3. Immunogenicity
Subgroups for gender, age and study year
Notes Location: Dong Thap Province, Mekong Delta, Vietnam
Socioeconomic description: rural; low income
Setting: home
Date: 1998 to 2000
Sex, age at vaccination, household composition and size and interval between the 2
injections similar in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Identical looking vaccine and placebo were
randomly numbered 0 to 9 and packaged
in packets of 10; however, unclear how ran-
domization sequence generated
Allocation concealment (selection bias) Low risk Code identifying identical-looking vaccine
and placebo was kept at the central phar-
macy
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind. Vaccine and placebo vials in-
distinguishable
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported on
Other bias Low risk None
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Olanratmanee 1992 THA
Methods Design: individual-RCT
Active surveillance for adverse events: 1.5 hours of observation and parental reporting
via adverse event report sheet
Participants Number: 170
Inclusion criteria: age 4 to 6 years; no further details
Exclusion criteria: no details
Interventions 1. Liquid formulation of S. typhi, TY21a: 88 participants
2. Placebo: 82 participants
Route and schedule: oral solution; 3 doses, alternate days
Concomitant medication: not specified
Outcomes 1. Adverse events
2. Immunogenicity
Notes Location: Thailand
Socioeconomic description: no details
Setting: clinic
Date: no details
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: not
mentioned
Allocation concealment (selection bias) Unclear risk Allocation concealment: no information
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind. Identical vaccine and
placebo packages
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
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Simanjuntak 1991i IDN
Methods Design: individual-RCT
Intermediate surveillance for efficacy: isolation of S. typhi from blood during trial (2.5
years)
Surveillance for adverse events: questionnaires collected from 588 individuals
Participants Number: 10,212
Inclusion criteria: age 3 to 44 years; no further details
Exclusion criteria: pregnant women; febrile illness
Interventions 1. Liquid formulation of S. typhi, Ty21a: 5066 participants
2. Placebo: 5146 participants
Route and schedule: oral solution; 3 doses, 1 week apart
Concomitant medication: not specified
Note Simanjuntak 1991ii IDN is a different arm of the same trial (see below for further
details). Simanjuntak 1991i IDN and Simanjuntak 1991ii IDN had different placebo
groups
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Adverse events
Subgroups for age and study year
Notes Location: Plaju and Sungai Gerong, Sumatra, Indonesia
Socioeconomic description: no details
Setting: clinic
Date: 1986 to 1989
Sex, age at vaccination, residence in a compound, history of typhoid vaccination and
level of education similar in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of allocation sequence: com-
puter-generated table of random numbers
Allocation concealment (selection bias) Low risk Identical vaccine and placebo
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind. Identical vaccine and
placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93% of participants (20,543/22,001) re-
ceived 3doses and included in results.Miss-
ing outcome data balanced across interven-
tion and control groups
Selective reporting (reporting bias) Low risk All expected outcomes reported on
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Simanjuntak 1991i IDN (Continued)
Other bias Low risk None
Simanjuntak 1991ii IDN
Methods See Simanjuntak 1991i IDN (Simanjuntak 1991ii IDN is a different arm of the same
trial)
Details as for Levine 1990i CHL, except surveillance for adverse events: questionnaires
collected from 602 individuals
Participants Details as for Simanjuntak 1991i IDN, except number: 10,331
Interventions 1. Enteric capsules of S. typhi, Ty21a: 5209 participants
2. Placebo: 5122 participants
Route and schedule: oral capsules; 3 doses, 1 week apart
Concomitant medication: not specified
Note Simanjuntak 1991i IDN is a different arm of the same trial (see below for further
details). Simanjuntak 1991i IDN and Simanjuntak 1991ii IDN had different placebo
groups
Outcomes Details as for Simanjuntak 1991i IDN
Notes Details as for Simanjuntak 1991i IDN
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Details as for Simanjuntak 1991i IDN
Allocation concealment (selection bias) Low risk Details as for Simanjuntak 1991i IDN
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Simanjuntak 1991i IDN
Incomplete outcome data (attrition bias)
All outcomes
Low risk Details as for Simanjuntak 1991i IDN
Selective reporting (reporting bias) Low risk Details as for Simanjuntak 1991i IDN
Other bias Low risk Details as for Simanjuntak 1991i IDN
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Sur 2009 IND
Methods Design: cluster (geographic clusters)-RCT
Active surveillance for efficacy: five study clinics were established to conduct surveillance
for febrile illnesses and to refer participants with severe disease for hospital care during
study period (2 years)
Surveillance period adverse events: all participants 30minutes after vaccination, subgroup
of 320 participants for 3 consecutive days, passive surveillance for adverse events for 1
month at all study clinics and hospitals
Participants 37,673 participants
80 contiguous geographic clusters (40 clusters in each study group)
Inclusion criteria: 24 months of age and older, no reported fever or had an axillary
temperature not greater than 37.5 °C at time of administration
Exclusion criteria: not stated
Interventions Single-dose capsular polysaccharide of S. typhi, Vi vaccine (dose 25 mcg) or inactivated
hepatitis A vaccine (dose 720 IU for children 2 to 18, 1440 IU for adults)
Route and schedule: single intramuscular injection, Vi vaccine or inactivated hepatitis
A vaccine
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Indirect protection from typhoid fever
3. Adverse events
Notes Location: Kolkata, India
Socioeconomic description: slum-dwelling residents
The clusters were stratified according to ward and the number of residents who were 18
years of age or younger (< 200 vs≥ 200 persons) and the number of residents who were
older than 18 years (< 500 vs ≥ 500 persons), resulting in eight strata
Date: November 2004 to December 2006
Setting: vaccination centres set up for each cluster and health clinics
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Used a table of random numbers to assign
half the 80 clusters to each vaccine”
Allocation concealment (selection bias) Low risk “The vaccines were labelled only with code
letters.” However, two vaccines were not
packaged in an identical fashion. Attempts
to minimize this bias unlikely to have af-
fected the findings of the trial
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and study personnel blind.
Not stated whether outcome assessors were
blinded
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Sur 2009 IND (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing data given (migra-
tion, dying fromother causes) andbalanced
across groups
Selective reporting (reporting bias) Low risk Study protocol not available but published
study reports on both primary and sec-
ondary outcomes
Other bias Low risk No recruitment bias, no baseline imbal-
ance, no loss of clusters, analysis adjusted
for clustering using generalized estimating
equation
Thiem 2011 VNM
Methods Design: individual-RCT
Active surveillance adverse events: Participants were observed at the clinic for 30 minutes
after injection. They were visited by the commune health staff 6, 24 and 48 hours after
each vaccination for measurement of temperature and inspection of the injection sites
Participants 301 full-term infants
Inclusion criteria: full-term, birth weight > 2500 g
Exclusion criteria: born to mothers with serious medical problems
Interventions Three arms:
Vi-r EPA and expanded programme on immunization (EPI) versus Hib-TT and EPI
versus EPI only
Route and schedule: intramuscular injection, infants vaccinated at 2, 4, 6 and 12 months
Outcomes 1. Adverse events
Notes Location: Thanh Thuy District, Phu Tho Province, Vietnam
Socioeconomic description: rural area
Date: not stated
Setting: community health centre and district hospital
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information to permit judge-
ment
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
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Thiem 2011 VNM (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 318 infants were randomly assigned. 301
infants received the first injection, 294 the
second, 283 the third and 167 the fourth
of either Vi-rEPA or Hib-TT. Reasons for
missing data given
Selective reporting (reporting bias) Low risk Expected outcomes reported on
Other bias Low risk None
Wahdan 1980a EGY
Methods Design: cluster (classroom)-RCT
Intermediate surveillance for efficacy: isolation of S. typhi from blood in the hospital
during the study (3 years)
Surveillance for adverse events: no details
Participants Number: 32,388
Inclusion criteria: age 6 to 7 years; no further details
Exclusion criteria: no details
Interventions 1. Liquid formulation of S. typhi, Ty21a: 16,486 participants
2. Placebo: 15,902 participants
Route and schedule: oral solution; 3 doses, alternate days
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Adverse events
Notes Location: Alexandria, Egypt
Socioeconomic description: no details
Setting: school
Date: 1978 to 1981
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Unclear risk Vaccine and placebo identical. Allocation
concealment unclear
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Wahdan 1980a EGY (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Vaccine and placebo identical
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported on
Other bias Unclear risk Analysis not adjustment for clustering
Wahdan 1980b EGY
Methods Design: cluster (classroom)-RCT
Surveillance for adverse events: no details
Participants Number: 884
Inclusion criteria: age 6 to 7 years; no further details
Exclusion criteria: no details
Interventions 1. Liquid formulation of S. typhi, Ty21a: 413 participants
2. Placebo: 471 participants
Route and schedule: oral solution; 3 doses, alternate days
Concomitant medication: not specified
Outcomes 1. Adverse events
Notes Location: Alexandria, Egypt
Socioeconomic description: no details
Setting: school
Date: 1978
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Unclear risk Vaccine and placebo identical. Allocation
concealment unclear
Blinding (performance bias and detection
bias)
All outcomes
Low risk Vaccine and placebo identical
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Wahdan 1980b EGY (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Unclear risk All expected outcomes reported on
Other bias Unclear risk Analysis not adjusted for clustering
Wang 1997a CHN
Methods Design: individual-RCT
Passive surveillance for efficacy: signs and symptoms of typhoid fever; blood cultures and
serum Widal’s test (1 year)
Participants Number: 81,506
Inclusion criteria: age 5 to 55 years; healthy
Exclusion criteria: history of liver, kidney or heart disease; hypertension; acute infection;
psychiatric disease; allergic history; prior typhoid infection; pregnancy; prior typhoid
vaccination in the last 2 years
Interventions 1. Capsular polysaccharide of S. typhi, Vi vaccine: 30 µg Vi: 41,118 participants
2. Meningococcal vaccine: 40,388 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Adverse reactions
Subgroups for age and gender
Notes Location: Baoying County, Jiangsu Province, China
Socioeconomic description: no details
Setting: no details
Date: 1994 to 1995
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of allocation sequence: com-
puter-generated random numbers ?
Allocation concealment (selection bias) Low risk Allocation concealment: code concealed
from field workers and study population
51Vaccines for preventing typhoid fever (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wang 1997a CHN (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind. Identical vaccine and
placebo vials
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported on
Other bias Low risk None
Wang 1997b CHN
Methods Design: individual-RCT
Surveillance for adverse events: fever and local symptoms checked before immunization,
and 6 to 8, 24 and 48 hours after immunization
Participants Number: 777
Inclusion criteria: > 6 years old; healthy
Exclusion criteria: no details
Interventions 1. Capsular polysaccharide of S. typhi, Vi vaccine: 30 µg Vi; 384 participants
2. Meningococcal vaccine: 393 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
Outcomes 1. Adverse reactions
Notes Location: Baoying County, Jiangsu Province, China
Socioeconomic description: no details
Setting: no details
Date: 1994
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of allocation sequence: com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Allocation concealment: code concealed
from field workers and study population
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind. Vaccine and placebo identi-
cal
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Wang 1997b CHN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Yang 2001 CHN
Methods Design: individual-RCT
Passive surveillance for efficacy: clinical symptoms; positive blood cultures and serum
Widal’s test during trial (1.6 years)
Surveillance for adverse events: parental reporting of adverse effects in 3 schools
Participants Number: 131,271
Inclusion criteria: healthy children age 3 to 19 years and adults age < 51 years
Exclusion criteria: chronic disease; under medication; pregnancy
Interventions 1. Capsular polysaccharide of S. typhi, Vi vaccine: 30 µg Vi; 65,287 participants
2. Placebo: 65,984 participants
Route and schedule: hypodermically; 1 dose
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. typhi bacteraemia)
2. Adverse events
Subgroups for age, profession and sex
Notes Location: County of Quan, north-eastern part of Guangxi Zhuang
Autonomous Region, southern China
Socioeconomic description: no details
Setting: clinic
Date: 1995 to 1996
Age, sex and profession similar in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of allocation sequence: unique
serial number to each participant; having
an even or an odd number determined al-
location to vaccine or placebo
Allocation concealment (selection bias) Low risk Allocation concealment: code concealed
from field workers and study population
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Yang 2001 CHN (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Zhou 2007 CHN
Methods Design: individual-RCT
Active surveillance for adverse events: All participants were observed for 2 hours at the
vaccination
site after administration of the study agent and were visited by trained clinicians on days
1, 2, 3 and 28
Participants Number: 667
Inclusion criteria: school children ages 9 to 14 who have previously received a primary
dose of Vi vaccine, no signs or symptoms consistent with an infection within the 2 weeks
before injection, no history of typhoid fever and axillary temperature of 37.5 °C on the
day of the planned injection
Exclusion criteria: no previous primary dose of Vi vaccine, signs or symptoms of infection
within the 2 weeks before injection, history of typhoid fever or axillary temperature
higher than 37.5 °C on day of planned injection
Interventions 1. Capsular polysaccharide of S. typhi, Vi vaccine to previously vaccinated children
(revaccination), 334 participants
2. Placebo (normal saline), 333 participants
Route and schedule: intramuscular injection, one dose
Outcomes 1. Adverse events
Notes Location: Suzhou, Jiangsu, China
Socioecomic description: no details
Setting: school
Date: 2002
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated random numbers”
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Zhou 2007 CHN (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind-blinding of participants and
study personnel. Vaccine and placebo iden-
tical
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Cluster-RCT: randomized controlled trial that randomly assigned clusters (eg, classrooms); ELISA: enzyme-linked immunosorbent
assay; individual-RCT: randomized controlled trial that randomly assigned individual participants; WHO: World Health Organi-
zation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ali 2011 No relevant outcome measures
Arya 1997 Letter; not an RCT
Ashcroft 1967 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Black 1983 No relevant outcome measures
Bumann 2001 Evaluated experimental live-attenuated oral vaccine candidates; no efficacy trials of this vaccine
Cahn 2004 Study arms randomly assigned to receive different doses of same vaccine
Chuttani 1977 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Cordero-Yap 2001 Compared 2 Vi polysaccharide vaccines made by 2 different companies
Cryz 1995 No relevant control group
Cumberland 1992 Evaluated Vi vaccine versus inactivated whole-cell vaccine, which is no longer in use
Ferreccio 1989 RCT compared different doses of the Ty21a vaccine
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(Continued)
Hejfec 1965 Two separate randomized trials, described together; none of the chemical subunit vaccines that were studied
are in use
Hejfec 1966 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Hejfec 1968 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Hejfec 1969 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Hejfec 1976 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Hien 2010 Evaluated adverse events of new M01ZH09 vaccine, no efficacy trials of this vaccine
Hohmann 1996a No random allocation
Hohmann 1996b No random allocation
Kantele 2013 No relevant outcome measures
Keddy 1999 No relevant outcome measures
Khan 2007 Nonrandomized study
Khoo 1995 Evaluated safety of Vi vaccine compared with meningococcal vaccine or combination
Kirkpatrick 2006 Evaluated adverse events of new M01ZH09 vaccine; no efficacy trials of this vaccine
Lebacq 2001 Evaluated different brands of Vi vaccine
Levin 1975 No random allocation; compared Vi with inactivated whole-cell vaccine, which is no longer in use
Lyon 2010 Evaluated adverse events of new M01ZH09 vaccine; no efficacy trials of this vaccine
Murphy 1991 No random allocation to vaccine and placebo arms
Nisini 1993 No random allocation
Panchanathan 2001 Compared Vi vaccine with inactivated whole-cell vaccine, which is no longer in use
Polish committee 1966 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Sabitha 2004 Compared 2 brands of Vi vaccine
Tacket 1992 Evaluated experimental live-attenuated oral vaccine candidates; no efficacy trials of these vaccines
Tacket 1997 Evaluated experimental live-attenuated oral vaccine candidates; no efficacy trials of these vaccines
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(Continued)
Tacket 2000 Evaluated experimental live-attenuated oral vaccine candidates; no efficacy trials of these vaccines
Tapa 1975 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Thiem 2006 No relevant outcome measures
van Damme 2011 Evaluated adverse events of new conjugate vaccine (Vi-CRM); no efficacy trials of this vaccine
Wahdan 1975 Quasi-RCT evaluating the inactivated whole-cell vaccine, which is no longer in use
Wahid 2011 No relevant outcome measures
Yang 2005 No relevant outcome measures
Yang 2009 Safety only, evaluated different brands of same vaccine
Yug Ty Comm 1962 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Yug Ty Comm 1964 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Zhou 2008 CHN Safety only; evaluated different brands of same vaccine
RCT: randomized controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Chinnasami
Trial name or title A Clinical Trial to Study the Optimal Use of Conjugate Typhoid Vaccine-Single Dose vs Two Doses
Methods
Participants 400 healthy children between 6 months and 5 years of age
Interventions 1. Conjugated typhoid vaccination: two doses at two-month intervals, each dose 0.5 mL
2. Conjugated typhoid vaccination: single dose, dose 0.5 mL
Outcomes Seroconversion rate
Starting date December 2012
Contact information Dr Bilal Chinnasami
balajictriumphants@gmail.com
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Chinnasami (Continued)
Notes Location: Tamil Nadu, India
Clinical Trials Registry-India: CTRI/2010/091/003031
Darton 2012
Trial name or title Understanding Typhoid Disease After Vaccination: A Single Centre, Randomised, Doubleblind, Placebo
Controlled Study to Evaluate M01ZH09 in a Healthy Adult Challenge Model, Using Ty21a Vaccine as a
Positive Control
Methods
Participants 99 adults ages 18 to 60 years and in good health
Interventions 1. M10ZH09 vaccine
2. Ty21a vaccine
3. Vaccine placebo
Outcomes Diagnosis of typhoid fever (2 weeks after typhoid challenge)
Starting date July 2011
Contact information Thomas Darton
01865857420
Notes Location: Oxford, United Kingdom
National Clinical Trials identifier: NCT01405521
House 2011
Trial name or title A Phase II, Single-centre, Randomised, Single-blind Study to Evaluate Vi-CRM197 Against Historical Un-
vaccinated Controls in a Healthy Adult ChallengeModel,With a Vi-PS Vaccine Control Arm-Understanding
Immunity After Typhoid Vaccination
Methods
Participants 36 adults ages 18 to 60 years and in good health
Interventions 1. Vi-CRM197 conjugate vaccine
2. Vi-PS control arm
Outcomes Main objective: Using an established model of human typhoid infection, in which healthy adults are delib-
erately infected with typhoid-causing bacteria, we will determine how effective a new typhoid vaccine (Vi-
CRM197, Novartis Vaccine Institute for Global Health) is in preventing infection
Primary end point(s): the proportion of participants developing typhoid fever after challenge with S. typhi
(Quailes strain) given 28 days after vaccination with NVGH Vi-CRM197 vaccine
Starting date December 2011
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House 2011 (Continued)
Contact information Ms Heather House
heather.house@admin.ox.ac.uk
Notes Location: Oxford, United Kingdom
EU Clinical Trials Registration identifier: EUCTR2011-003653-26-GB
Mitra 2012
Trial name or title Incidence of Typhoid Fever as Observed Over 1 Year in Children Aged 6 Months-12 Years After Receiving
Conjugated Typhoid Vaccine (Peda Typh TM) Versus a Similar Non-vaccinated Group in the Same Locality
in Kolkata
Methods
Participants 2000 healthy children and teenagers of both sexes from 6 months to 12 years of age
Interventions 1. Vi-Tetanus toxoid conjugated typhoid vaccine (Peda Typh TM)
2. Nil
Outcomes Incidence of typhoid fever and paratyphoid fever in the vaccinated and non vaccinated groups
Starting date July 2012
Contact information Dr Monjori Mitra
monjorim@medclinsearch.com
Notes Location: Kolkata, India
Clinical Trials Registry-India: CTRI/2012/06/002719
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D A T A A N D A N A L Y S E S
Comparison 1. Ty21a vaccine (three doses) vs control; efficacy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of typhoid fever, Year
1
2 20543 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.46, 0.92]
1.1 Enteric capsules 1 10331 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.45, 1.15]
1.2 Liquid formulation 1 10212 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.35, 0.96]
2 Incidence of typhoid fever, Year
2
2 20543 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.29, 0.60]
2.1 Enteric capsules 1 10331 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.30, 0.79]
2.2 Liquid formulation 1 10212 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.20, 0.59]
3 Incidence of typhoid fever, Year
3
2 20543 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.28, 1.06]
3.1 Enteric capsules 1 10331 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.18, 1.31]
3.2 Liquid formulation 1 10212 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.23, 1.50]
4 Cumulative incidence of typhoid
fever at 2.5 to 3 years
2 20543 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.42, 0.66]
4.1 Enteric capsules 1 10331 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.42, 0.79]
4.2 Liquid formulation 1 10212 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.33, 0.66]
Comparison 2. Ty21a vaccine: liquid formulation vs enteric capsules (3 doses)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cumulative incidence of typhoid
fever at 2.5 to 3 years
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 3. Ty21a vaccine vs control; adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever 4 2066 Risk Ratio (M-H, Random, 95% CI) 1.84 [1.02, 3.31]
1.1 Enteric capsules 2 1141 Risk Ratio (M-H, Random, 95% CI) 2.72 [1.06, 6.96]
1.2 Liquid formulation 1 588 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.61, 3.03]
1.3 In milk with sodium
bicarbonate
1 337 Risk Ratio (M-H, Random, 95% CI) 2.08 [0.19, 22.77]
2 Vomiting 4 2066 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.43, 3.05]
2.1 Enteric capsules 2 1141 Risk Ratio (M-H, Random, 95% CI) 1.92 [0.13, 27.74]
2.2 Liquid formulation 1 588 Risk Ratio (M-H, Random, 95% CI) 1.91 [0.37, 9.79]
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2.3 In milk with sodium
bicarbonate
1 337 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.33, 1.31]
3 Diarrhoea 4 2066 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.52, 1.24]
3.1 Enteric capsules 2 1141 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.57, 2.58]
3.2 Liquid formulation 1 588 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.34, 1.49]
3.3 In milk with sodium
bicarbonate
1 337 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.29, 1.30]
4 Nausea or abdominal pain 4 2066 Risk Ratio (M-H, Random, 95% CI) 1.70 [0.77, 3.75]
4.1 Enteric capsules 2 1141 Risk Ratio (M-H, Random, 95% CI) 2.92 [1.53, 5.57]
4.2 Liquid formulation 1 588 Risk Ratio (M-H, Random, 95% CI) 1.84 [0.90, 3.77]
4.3 In milk with sodium
bicarbonate
1 337 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.39, 1.13]
5 Headache 2 1190 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.76, 2.27]
5.1 Enteric capsules 1 602 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.64, 3.07]
5.2 Liquid formulation 1 588 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.57, 2.65]
6 Rash 2 1190 Risk Ratio (M-H, Random, 95% CI) 2.94 [0.61, 14.12]
6.1 Enteric capsules 1 602 Risk Ratio (M-H, Random, 95% CI) 2.81 [0.29, 26.83]
6.2 Liquid formulation 1 588 Risk Ratio (M-H, Random, 95% CI) 3.06 [0.34, 27.24]
7 Any mild adverse event 3 1360 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.03, 2.72]
7.1 Enteric capsules 1 602 Risk Ratio (M-H, Random, 95% CI) 1.78 [1.08, 2.95]
7.2 Liquid formulation 2 758 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.06, 8.55]
8 Serious adverse events 5 2236 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Enteric capsules 2 1141 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Liquid formulation 2 758 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 In milk with sodium
bicarbonate
1 337 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Vi polysaccharide vaccine (one dose) vs control; efficacy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of typhoid fever 6 Risk Ratio (Random, 95% CI) Subtotals only
1.1 Year 1 3 99797 Risk Ratio (Random, 95% CI) 0.31 [0.26, 0.37]
1.2 Year 2 4 194969 Risk Ratio (Random, 95% CI) 0.41 [0.31, 0.55]
1.3 Year 3 1 11384 Risk Ratio (Random, 95% CI) 0.50 [0.32, 0.78]
2 Cumulative incidence of typhoid
fever at 2.5 to 3 years
1 11384 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.30, 0.70]
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Comparison 5. Vi polysaccharide vaccine vs control; adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever 4 133038 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.85, 1.14]
2 Erythema 3 132261 Risk Ratio (M-H, Random, 95% CI) 3.04 [0.45, 20.30]
3 Swelling at injection site 3 1767 Risk Ratio (M-H, Random, 95% CI) 6.06 [1.07, 34.22]
4 Pain at injection site 1 667 Risk Ratio (M-H, Random, 95% CI) 7.98 [3.69, 17.24]
5 Serious adverse events 4 133038 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Vi-rEPA vaccine (two doses) vs control; efficacy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of typhoid fever 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Year 1 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Year 2 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Vi-rEPA vaccine vs control; adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever after Vi-rEPA (dose1) 2 12209 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.57, 4.23]
2 Fever after Vi-rEPA (dose 2) 2 11286 Risk Ratio (M-H, Random, 95% CI) 2.29 [0.56, 9.46]
3 Erythema after Vi-rEPA (dose 1) 2 12209 Risk Ratio (M-H, Random, 95% CI) 3.03 [0.32, 28.64]
4 Erythema after Vi-rEPA (dose 2) 2 11286 Risk Ratio (M-H, Random, 95% CI) 2.01 [0.18, 22.21]
5 Swelling at injection site after
Vi-rEPA (dose 1)
2 12209 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.15, 7.03]
6 Swelling at injection site after
Vi-rEPA (dose 2)
2 11286 Risk Ratio (M-H, Random, 95% CI) 5.27 [0.26, 106.74]
7 Serious adverse events 2 12209 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
62Vaccines for preventing typhoid fever (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Ty21a vaccine (three doses) vs control; efficacy, Outcome 1 Incidence of
typhoid fever, Year 1.
Review: Vaccines for preventing typhoid fever
Comparison: 1 Ty21a vaccine (three doses) vs control; efficacy
Outcome: 1 Incidence of typhoid fever, Year 1
Study or subgroup Vaccine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Simanjuntak 1991ii IDN 30/5209 41/5122 53.2 % 0.72 [ 0.45, 1.15 ]
Subtotal (95% CI) 5209 5122 53.2 % 0.72 [ 0.45, 1.15 ]
Total events: 30 (Vaccine), 41 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
2 Liquid formulation
Simanjuntak 1991i IDN 24/5066 42/5146 46.8 % 0.58 [ 0.35, 0.96 ]
Subtotal (95% CI) 5066 5146 46.8 % 0.58 [ 0.35, 0.96 ]
Total events: 24 (Vaccine), 42 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
Total (95% CI) 10275 10268 100.0 % 0.65 [ 0.46, 0.92 ]
Total events: 54 (Vaccine), 83 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
0.01 0.1 1 10 100
Favours vaccine Favours control
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Analysis 1.2. Comparison 1 Ty21a vaccine (three doses) vs control; efficacy, Outcome 2 Incidence of
typhoid fever, Year 2.
Review: Vaccines for preventing typhoid fever
Comparison: 1 Ty21a vaccine (three doses) vs control; efficacy
Outcome: 2 Incidence of typhoid fever, Year 2
Study or subgroup Vaccine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Simanjuntak 1991ii IDN 25/5209 50/5122 56.6 % 0.49 [ 0.30, 0.79 ]
Subtotal (95% CI) 5209 5122 56.6 % 0.49 [ 0.30, 0.79 ]
Total events: 25 (Vaccine), 50 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
2 Liquid formulation
Simanjuntak 1991i IDN 17/5066 51/5146 43.4 % 0.34 [ 0.20, 0.59 ]
Subtotal (95% CI) 5066 5146 43.4 % 0.34 [ 0.20, 0.59 ]
Total events: 17 (Vaccine), 51 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.88 (P = 0.00011)
Total (95% CI) 10275 10268 100.0 % 0.42 [ 0.29, 0.60 ]
Total events: 42 (Vaccine), 101 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.01, df = 1 (P = 0.31); I2 =1%
Test for overall effect: Z = 4.71 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.01, df = 1 (P = 0.31), I2 =1%
0.01 0.1 1 10 100
Favours vaccine Favours control
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Analysis 1.3. Comparison 1 Ty21a vaccine (three doses) vs control; efficacy, Outcome 3 Incidence of
typhoid fever, Year 3.
Review: Vaccines for preventing typhoid fever
Comparison: 1 Ty21a vaccine (three doses) vs control; efficacy
Outcome: 3 Incidence of typhoid fever, Year 3
Study or subgroup Vaccine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Simanjuntak 1991ii IDN 6/5209 12/5122 47.5 % 0.49 [ 0.18, 1.31 ]
Subtotal (95% CI) 5209 5122 47.5 % 0.49 [ 0.18, 1.31 ]
Total events: 6 (Vaccine), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
2 Liquid formulation
Simanjuntak 1991i IDN 7/5066 12/5146 52.5 % 0.59 [ 0.23, 1.50 ]
Subtotal (95% CI) 5066 5146 52.5 % 0.59 [ 0.23, 1.50 ]
Total events: 7 (Vaccine), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 10275 10268 100.0 % 0.54 [ 0.28, 1.06 ]
Total events: 13 (Vaccine), 24 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.076)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.01 0.1 1 10 100
Favours vaccine Favours control
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Analysis 1.4. Comparison 1 Ty21a vaccine (three doses) vs control; efficacy, Outcome 4 Cumulative
incidence of typhoid fever at 2.5 to 3 years.
Review: Vaccines for preventing typhoid fever
Comparison: 1 Ty21a vaccine (three doses) vs control; efficacy
Outcome: 4 Cumulative incidence of typhoid fever at 2.5 to 3 years
Study or subgroup Vaccine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Simanjuntak 1991ii IDN 61/5209 104/5122 54.0 % 0.58 [ 0.42, 0.79 ]
Subtotal (95% CI) 5209 5122 54.0 % 0.58 [ 0.42, 0.79 ]
Total events: 61 (Vaccine), 104 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.44 (P = 0.00059)
2 Liquid formulation
Simanjuntak 1991i IDN 48/5066 104/5146 46.0 % 0.47 [ 0.33, 0.66 ]
Subtotal (95% CI) 5066 5146 46.0 % 0.47 [ 0.33, 0.66 ]
Total events: 48 (Vaccine), 104 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.37 (P = 0.000012)
Total (95% CI) 10275 10268 100.0 % 0.52 [ 0.42, 0.66 ]
Total events: 109 (Vaccine), 208 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 5.49 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.77, df = 1 (P = 0.38), I2 =0.0%
0.01 0.1 1 10 100
Favours vaccine Favours control
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Analysis 2.1. Comparison 2 Ty21a vaccine: liquid formulation vs enteric capsules (3 doses), Outcome 1
Cumulative incidence of typhoid fever at 2.5 to 3 years.
Review: Vaccines for preventing typhoid fever
Comparison: 2 Ty21a vaccine: liquid formulation vs enteric capsules (3 doses)
Outcome: 1 Cumulative incidence of typhoid fever at 2.5 to 3 years
Study or subgroup Liquid Enteric capsules Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Simanjuntak 1991ii IDN 48/5006 61/5209 0.82 [ 0.56, 1.19 ]
0.01 0.1 1 10 100
Favours liquid Favours enteric
Analysis 3.1. Comparison 3 Ty21a vaccine vs control; adverse events, Outcome 1 Fever.
Review: Vaccines for preventing typhoid fever
Comparison: 3 Ty21a vaccine vs control; adverse events
Outcome: 1 Fever
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Levine 1986i CHL 1/172 1/367 4.6 % 2.13 [ 0.13, 33.91 ]
Simanjuntak 1991ii IDN 15/311 5/291 34.9 % 2.81 [ 1.03, 7.63 ]
Subtotal (95% CI) 483 658 39.5 % 2.72 [ 1.06, 6.96 ]
Total events: 16 (Vaccine), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
2 Liquid formulation
Simanjuntak 1991i IDN 16/333 9/255 54.4 % 1.36 [ 0.61, 3.03 ]
Subtotal (95% CI) 333 255 54.4 % 1.36 [ 0.61, 3.03 ]
Total events: 16 (Vaccine), 9 (Placebo)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours vaccine Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.76 (P = 0.45)
3 In milk with sodium bicarbonate
Levine 1986ii CHL 2/165 1/172 6.1 % 2.08 [ 0.19, 22.77 ]
Subtotal (95% CI) 165 172 6.1 % 2.08 [ 0.19, 22.77 ]
Total events: 2 (Vaccine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 981 1085 100.0 % 1.84 [ 1.02, 3.31 ]
Total events: 34 (Vaccine), 16 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.044)
Test for subgroup differences: Chi2 = 1.22, df = 2 (P = 0.54), I2 =0.0%
0.01 0.1 1 10 100
Favours vaccine Favours placebo
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Analysis 3.2. Comparison 3 Ty21a vaccine vs control; adverse events, Outcome 2 Vomiting.
Review: Vaccines for preventing typhoid fever
Comparison: 3 Ty21a vaccine vs control; adverse events
Outcome: 2 Vomiting
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Levine 1986i CHL 4/172 1/367 14.4 % 8.53 [ 0.96, 75.79 ]
Simanjuntak 1991ii IDN 3/311 5/291 24.4 % 0.56 [ 0.14, 2.33 ]
Subtotal (95% CI) 483 658 38.8 % 1.92 [ 0.13, 27.74 ]
Total events: 7 (Vaccine), 6 (Placebo)
Heterogeneity: Tau2 = 2.86; Chi2 = 4.23, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Liquid formulation
Simanjuntak 1991i IDN 5/333 2/255 21.0 % 1.91 [ 0.37, 9.79 ]
Subtotal (95% CI) 333 255 21.0 % 1.91 [ 0.37, 9.79 ]
Total events: 5 (Vaccine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
3 In milk with sodium bicarbonate
Levine 1986ii CHL 12/165 19/172 40.2 % 0.66 [ 0.33, 1.31 ]
Subtotal (95% CI) 165 172 40.2 % 0.66 [ 0.33, 1.31 ]
Total events: 12 (Vaccine), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
Total (95% CI) 981 1085 100.0 % 1.15 [ 0.43, 3.05 ]
Total events: 24 (Vaccine), 27 (Placebo)
Heterogeneity: Tau2 = 0.50; Chi2 = 6.16, df = 3 (P = 0.10); I2 =51%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 1.82, df = 2 (P = 0.40), I2 =0.0%
0.01 0.1 1 10 100
Favours vaccine Favours placebo
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Analysis 3.3. Comparison 3 Ty21a vaccine vs control; adverse events, Outcome 3 Diarrhoea.
Review: Vaccines for preventing typhoid fever
Comparison: 3 Ty21a vaccine vs control; adverse events
Outcome: 3 Diarrhoea
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Levine 1986i CHL 2/172 4/367 6.6 % 1.07 [ 0.20, 5.77 ]
Simanjuntak 1991ii IDN 12/311 9/291 25.9 % 1.25 [ 0.53, 2.92 ]
Subtotal (95% CI) 483 658 32.5 % 1.21 [ 0.57, 2.58 ]
Total events: 14 (Vaccine), 13 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
2 Liquid formulation
Simanjuntak 1991i IDN 13/333 14/255 34.4 % 0.71 [ 0.34, 1.49 ]
Subtotal (95% CI) 333 255 34.4 % 0.71 [ 0.34, 1.49 ]
Total events: 13 (Vaccine), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
3 In milk with sodium bicarbonate
Levine 1986ii CHL 10/165 17/172 33.1 % 0.61 [ 0.29, 1.30 ]
Subtotal (95% CI) 165 172 33.1 % 0.61 [ 0.29, 1.30 ]
Total events: 10 (Vaccine), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 981 1085 100.0 % 0.80 [ 0.52, 1.24 ]
Total events: 37 (Vaccine), 44 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 1.72, df = 2 (P = 0.42), I2 =0.0%
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Analysis 3.4. Comparison 3 Ty21a vaccine vs control; adverse events, Outcome 4 Nausea or abdominal pain.
Review: Vaccines for preventing typhoid fever
Comparison: 3 Ty21a vaccine vs control; adverse events
Outcome: 4 Nausea or abdominal pain
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Levine 1986i CHL 11/172 9/367 23.6 % 2.61 [ 1.10, 6.18 ]
Simanjuntak 1991ii IDN 18/311 5/291 21.9 % 3.37 [ 1.27, 8.96 ]
Subtotal (95% CI) 483 658 45.5 % 2.92 [ 1.53, 5.57 ]
Total events: 29 (Vaccine), 14 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
2 Liquid formulation
Simanjuntak 1991i IDN 24/333 10/255 25.9 % 1.84 [ 0.90, 3.77 ]
Subtotal (95% CI) 333 255 25.9 % 1.84 [ 0.90, 3.77 ]
Total events: 24 (Vaccine), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
3 In milk with sodium bicarbonate
Levine 1986ii CHL 19/165 30/172 28.6 % 0.66 [ 0.39, 1.13 ]
Subtotal (95% CI) 165 172 28.6 % 0.66 [ 0.39, 1.13 ]
Total events: 19 (Vaccine), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 981 1085 100.0 % 1.70 [ 0.77, 3.75 ]
Total events: 72 (Vaccine), 54 (Placebo)
Heterogeneity: Tau2 = 0.49; Chi2 = 13.29, df = 3 (P = 0.004); I2 =77%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 13.06, df = 2 (P = 0.00), I2 =85%
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Analysis 3.5. Comparison 3 Ty21a vaccine vs control; adverse events, Outcome 5 Headache.
Review: Vaccines for preventing typhoid fever
Comparison: 3 Ty21a vaccine vs control; adverse events
Outcome: 5 Headache
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Simanjuntak 1991ii IDN 15/311 10/291 49.3 % 1.40 [ 0.64, 3.07 ]
Subtotal (95% CI) 311 291 49.3 % 1.40 [ 0.64, 3.07 ]
Total events: 15 (Vaccine), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
2 Liquid formulation
Simanjuntak 1991i IDN 16/333 10/255 50.7 % 1.23 [ 0.57, 2.65 ]
Subtotal (95% CI) 333 255 50.7 % 1.23 [ 0.57, 2.65 ]
Total events: 16 (Vaccine), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 644 546 100.0 % 1.31 [ 0.76, 2.27 ]
Total events: 31 (Vaccine), 20 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 3.6. Comparison 3 Ty21a vaccine vs control; adverse events, Outcome 6 Rash.
Review: Vaccines for preventing typhoid fever
Comparison: 3 Ty21a vaccine vs control; adverse events
Outcome: 6 Rash
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Simanjuntak 1991ii IDN 3/311 1/291 48.4 % 2.81 [ 0.29, 26.83 ]
Subtotal (95% CI) 311 291 48.4 % 2.81 [ 0.29, 26.83 ]
Total events: 3 (Vaccine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
2 Liquid formulation
Simanjuntak 1991i IDN 4/333 1/255 51.6 % 3.06 [ 0.34, 27.24 ]
Subtotal (95% CI) 333 255 51.6 % 3.06 [ 0.34, 27.24 ]
Total events: 4 (Vaccine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 644 546 100.0 % 2.94 [ 0.61, 14.12 ]
Total events: 7 (Vaccine), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 3.7. Comparison 3 Ty21a vaccine vs control; adverse events, Outcome 7 Any mild adverse event.
Review: Vaccines for preventing typhoid fever
Comparison: 3 Ty21a vaccine vs control; adverse events
Outcome: 7 Any mild adverse event
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Simanjuntak 1991ii IDN 40/311 21/291 48.4 % 1.78 [ 1.08, 2.95 ]
Subtotal (95% CI) 311 291 48.4 % 1.78 [ 1.08, 2.95 ]
Total events: 40 (Vaccine), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.024)
2 Liquid formulation
Olanratmanee 1992 THA 0/88 3/82 2.7 % 0.13 [ 0.01, 2.54 ]
Simanjuntak 1991i IDN 47/333 20/255 49.0 % 1.80 [ 1.09, 2.96 ]
Subtotal (95% CI) 421 337 51.6 % 0.74 [ 0.06, 8.55 ]
Total events: 47 (Vaccine), 23 (Placebo)
Heterogeneity: Tau2 = 2.30; Chi2 = 2.98, df = 1 (P = 0.08); I2 =66%
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 732 628 100.0 % 1.67 [ 1.03, 2.72 ]
Total events: 87 (Vaccine), 44 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.98, df = 2 (P = 0.23); I2 =33%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%
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Analysis 3.8. Comparison 3 Ty21a vaccine vs control; adverse events, Outcome 8 Serious adverse events.
Review: Vaccines for preventing typhoid fever
Comparison: 3 Ty21a vaccine vs control; adverse events
Outcome: 8 Serious adverse events
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Enteric capsules
Levine 1986i CHL 0/172 0/367 Not estimable
Simanjuntak 1991ii IDN 0/311 0/291 Not estimable
Subtotal (95% CI) 483 658 Not estimable
Total events: 0 (Vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Liquid formulation
Olanratmanee 1992 THA 0/88 0/82 Not estimable
Simanjuntak 1991i IDN 0/333 0/255 Not estimable
Subtotal (95% CI) 421 337 Not estimable
Total events: 0 (Vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 In milk with sodium bicarbonate
Levine 1986ii CHL 0/165 0/172 Not estimable
Subtotal (95% CI) 165 172 Not estimable
Total events: 0 (Vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1069 1167 Not estimable
Total events: 0 (Vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.0, df = -1 (P = 0.0), I2 =0.0%
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Analysis 4.1. Comparison 4 Vi polysaccharide vaccine (one dose) vs control; efficacy, Outcome 1 Incidence
of typhoid fever.
Review: Vaccines for preventing typhoid fever
Comparison: 4 Vi polysaccharide vaccine (one dose) vs control; efficacy
Outcome: 1 Incidence of typhoid fever
Study or subgroup Vaccine Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Year 1
Acharya 1987 NPL 3457 3450 -1.273 (0.1174) 41.7 % 0.28 [ 0.22, 0.35 ]
Klugman 1987 ZAF 5692 5692 -0.942 (0.1684) 24.8 % 0.39 [ 0.28, 0.54 ]
Wang 1997a CHN 41118 40388 -1.238 (0.1378) 33.5 % 0.29 [ 0.22, 0.38 ]
Subtotal (95% CI) 50267 49530 100.0 % 0.31 [ 0.26, 0.37 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.79, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 12.47 (P < 0.00001)
2 Year 2
Khan 2012 PAK 13238 13993 -0.411 (0.2273) 19.3 % 0.66 [ 0.42, 1.04 ]
Klugman 1987 ZAF 5692 5692 -0.734 (0.1811) 23.2 % 0.48 [ 0.34, 0.68 ]
Sur 2009 IND 12206 12877 -1.079 (0.0921) 31.4 % 0.34 [ 0.28, 0.41 ]
Yang 2001 CHN 65287 65984 -1.171 (0.1505) 26.1 % 0.31 [ 0.23, 0.42 ]
Subtotal (95% CI) 96423 98546 100.0 % 0.41 [ 0.31, 0.55 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 10.87, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 6.09 (P < 0.00001)
3 Year 3
Klugman 1987 ZAF 5692 5692 -0.693 (0.227) 100.0 % 0.50 [ 0.32, 0.78 ]
Subtotal (95% CI) 5692 5692 100.0 % 0.50 [ 0.32, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 5.47, df = 2 (P = 0.07), I2 =63%
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Analysis 4.2. Comparison 4 Vi polysaccharide vaccine (one dose) vs control; efficacy, Outcome 2
Cumulative incidence of typhoid fever at 2.5 to 3 years.
Review: Vaccines for preventing typhoid fever
Comparison: 4 Vi polysaccharide vaccine (one dose) vs control; efficacy
Outcome: 2 Cumulative incidence of typhoid fever at 2.5 to 3 years
Study or subgroup Vaccine Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Klugman 1987 ZAF 30/5692 66/5692 100.0 % 0.45 [ 0.30, 0.70 ]
Total (95% CI) 5692 5692 100.0 % 0.45 [ 0.30, 0.70 ]
Total events: 30 (Vaccine), 66 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.59 (P = 0.00033)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 5.1. Comparison 5 Vi polysaccharide vaccine vs control; adverse events, Outcome 1 Fever.
Review: Vaccines for preventing typhoid fever
Comparison: 5 Vi polysaccharide vaccine vs control; adverse events
Outcome: 1 Fever
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Keitel 1994 USA 3/237 1/86 0.4 % 1.09 [ 0.11, 10.33 ]
Wang 1997a CHN 4/384 0/393 0.3 % 9.21 [ 0.50, 170.49 ]
Yang 2001 CHN 325/65287 336/65984 95.9 % 0.98 [ 0.84, 1.14 ]
Zhou 2007 CHN 11/334 12/333 3.4 % 0.91 [ 0.41, 2.04 ]
Total (95% CI) 66242 66796 100.0 % 0.98 [ 0.85, 1.14 ]
Total events: 343 (Vaccine), 349 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.31, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Vi polysaccharide vaccine vs control; adverse events, Outcome 2 Erythema.
Review: Vaccines for preventing typhoid fever
Comparison: 5 Vi polysaccharide vaccine vs control; adverse events
Outcome: 2 Erythema
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Keitel 1994 USA 16/237 0/86 24.5 % 12.06 [ 0.73, 198.92 ]
Yang 2001 CHN 325/65287 336/65984 52.1 % 0.98 [ 0.84, 1.14 ]
Zhou 2007 CHN 4/334 0/333 23.4 % 8.97 [ 0.49, 166.01 ]
Total (95% CI) 65858 66403 100.0 % 3.04 [ 0.45, 20.30 ]
Total events: 345 (Vaccine), 336 (Placebo)
Heterogeneity: Tau2 = 1.80; Chi2 = 5.36, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Vi polysaccharide vaccine vs control; adverse events, Outcome 3 Swelling at
injection site.
Review: Vaccines for preventing typhoid fever
Comparison: 5 Vi polysaccharide vaccine vs control; adverse events
Outcome: 3 Swelling at injection site
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Keitel 1994 USA 16/237 0/86 38.1 % 12.06 [ 0.73, 198.92 ]
Wang 1997a CHN 2/384 0/393 32.6 % 5.12 [ 0.25, 106.24 ]
Zhou 2007 CHN 1/334 0/333 29.3 % 2.99 [ 0.12, 73.16 ]
Total (95% CI) 955 812 100.0 % 6.06 [ 1.07, 34.22 ]
Total events: 19 (Vaccine), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Vi polysaccharide vaccine vs control; adverse events, Outcome 4 Pain at
injection site.
Review: Vaccines for preventing typhoid fever
Comparison: 5 Vi polysaccharide vaccine vs control; adverse events
Outcome: 4 Pain at injection site
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Zhou 2007 CHN 56/334 7/333 100.0 % 7.98 [ 3.69, 17.24 ]
Total (95% CI) 334 333 100.0 % 7.98 [ 3.69, 17.24 ]
Total events: 56 (Vaccine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.28 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Vi polysaccharide vaccine vs control; adverse events, Outcome 5 Serious
adverse events.
Review: Vaccines for preventing typhoid fever
Comparison: 5 Vi polysaccharide vaccine vs control; adverse events
Outcome: 5 Serious adverse events
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Keitel 1994 USA 0/237 0/86 Not estimable
Wang 1997a CHN 0/384 0/393 Not estimable
Yang 2001 CHN 0/65287 0/65984 Not estimable
Zhou 2007 CHN 0/334 0/333 Not estimable
Total (95% CI) 66242 66796 Not estimable
Total events: 0 (Vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Vi-rEPA vaccine (two doses) vs control; efficacy, Outcome 1 Incidence of
typhoid fever.
Review: Vaccines for preventing typhoid fever
Comparison: 6 Vi-rEPA vaccine (two doses) vs control; efficacy
Outcome: 1 Incidence of typhoid fever
Study or subgroup Vaccine Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Year 1
Lin 2001 VNM 2/5991 33/6017 0.06 [ 0.01, 0.25 ]
2 Year 2
Lin 2001 VNM 3/5991 23/6017 0.13 [ 0.04, 0.44 ]
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Analysis 7.1. Comparison 7 Vi-rEPA vaccine vs control; adverse events, Outcome 1 Fever after Vi-rEPA
(dose1).
Review: Vaccines for preventing typhoid fever
Comparison: 7 Vi-rEPA vaccine vs control; adverse events
Outcome: 1 Fever after Vi-rEPA (dose1)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 2001 VNM 81/5991 32/6017 51.1 % 2.54 [ 1.69, 3.82 ]
Thiem 2011 VNM 22/100 24/101 48.9 % 0.93 [ 0.56, 1.54 ]
Total (95% CI) 6091 6118 100.0 % 1.55 [ 0.57, 4.23 ]
Total events: 103 (Vaccine), 56 (Placebo)
Heterogeneity: Tau2 = 0.47; Chi2 = 9.47, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Vi-rEPA vaccine vs control; adverse events, Outcome 2 Fever after Vi-rEPA
(dose 2).
Review: Vaccines for preventing typhoid fever
Comparison: 7 Vi-rEPA vaccine vs control; adverse events
Outcome: 2 Fever after Vi-rEPA (dose 2)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 2001 VNM 109/5525 25/5566 55.1 % 4.39 [ 2.85, 6.77 ]
Thiem 2011 VNM 7/96 7/99 44.9 % 1.03 [ 0.38, 2.83 ]
Total (95% CI) 5621 5665 100.0 % 2.29 [ 0.56, 9.46 ]
Total events: 116 (Vaccine), 32 (Placebo)
Heterogeneity: Tau2 = 0.90; Chi2 = 6.73, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Vi-rEPA vaccine vs control; adverse events, Outcome 3 Erythema after Vi-rEPA
(dose 1).
Review: Vaccines for preventing typhoid fever
Comparison: 7 Vi-rEPA vaccine vs control; adverse events
Outcome: 3 Erythema after Vi-rEPA (dose 1)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 2001 VNM 0/5991 0/6017 Not estimable
Thiem 2011 VNM 3/100 1/101 100.0 % 3.03 [ 0.32, 28.64 ]
Total (95% CI) 6091 6118 100.0 % 3.03 [ 0.32, 28.64 ]
Total events: 3 (Vaccine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Vi-rEPA vaccine vs control; adverse events, Outcome 4 Erythema after Vi-rEPA
(dose 2).
Review: Vaccines for preventing typhoid fever
Comparison: 7 Vi-rEPA vaccine vs control; adverse events
Outcome: 4 Erythema after Vi-rEPA (dose 2)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 2001 VNM 2/5525 1/5566 100.0 % 2.01 [ 0.18, 22.21 ]
Thiem 2011 VNM 0/96 0/99 Not estimable
Total (95% CI) 5621 5665 100.0 % 2.01 [ 0.18, 22.21 ]
Total events: 2 (Vaccine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Vi-rEPA vaccine vs control; adverse events, Outcome 5 Swelling at injection site
after Vi-rEPA (dose 1).
Review: Vaccines for preventing typhoid fever
Comparison: 7 Vi-rEPA vaccine vs control; adverse events
Outcome: 5 Swelling at injection site after Vi-rEPA (dose 1)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 2001 VNM 0/5991 0/6017 Not estimable
Thiem 2011 VNM 2/100 2/101 100.0 % 1.01 [ 0.15, 7.03 ]
Total (95% CI) 6091 6118 100.0 % 1.01 [ 0.15, 7.03 ]
Total events: 2 (Vaccine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Vi-rEPA vaccine vs control; adverse events, Outcome 6 Swelling at injection site
after Vi-rEPA (dose 2).
Review: Vaccines for preventing typhoid fever
Comparison: 7 Vi-rEPA vaccine vs control; adverse events
Outcome: 6 Swelling at injection site after Vi-rEPA (dose 2)
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 2001 VNM 20/5525 1/5566 54.9 % 20.15 [ 2.71, 150.08 ]
Thiem 2011 VNM 1/96 1/99 45.1 % 1.03 [ 0.07, 16.25 ]
Total (95% CI) 5621 5665 100.0 % 5.27 [ 0.26, 106.74 ]
Total events: 21 (Vaccine), 2 (Placebo)
Heterogeneity: Tau2 = 3.24; Chi2 = 3.14, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours experimental Favours control
Analysis 7.7. Comparison 7 Vi-rEPA vaccine vs control; adverse events, Outcome 7 Serious adverse events.
Review: Vaccines for preventing typhoid fever
Comparison: 7 Vi-rEPA vaccine vs control; adverse events
Outcome: 7 Serious adverse events
Study or subgroup Vaccine Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lin 2001 VNM 0/5991 0/6017 Not estimable
Thiem 2011 VNM 0/100 0/101 Not estimable
Total (95% CI) 6091 6118 Not estimable
Total events: 0 (Vaccine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Efficacy of Ty21a vaccine: unadjusted cluster-trial resultsa
Trial Year Preparation No. doses RR (95% CI)b Efficacy
Black 1990ii CHL 1 Enteric capsules 1 0.75 (0.51 to 1.09) 25% (-9% to 49%)
2 0.65 (0.39 to 1.08) 35% (-8% to 61%)
3 0.99 (0.52 to 1.87) 1% (-87% to 48%)
4 1.06 (0.63 to 1.77) -6% (-77% to 37%)
5 1.10 (0.57 to 2.13) -10% (-113% to 43%)
Black 1990ii CHL 1 Enteric capsules 2 0.48 (0.31 to 0.74) 52% (24% to 69%)
2 0.29 (0.15 to 0.56) 71% (44% to 85%)
3 0.78 (0.40 to 1.54) 22% (-54% to 60%)
4 0.81 (0.47 to 1.41) 19% (-41% to 53%)
5 0.93 (0.47 to 1.84) 7% (-84% to 53%)
Levine 1987ii CHL 1 Enteric capsules 3 0.29 (0.12 to 0.67) 71% (33% to 88%)
2 0.40 (0.17 to 0.90) 60% (10% to 83%)
3 0.33 (0.15 to 0.73) 67% (27% to 85%)
4 0.22 (0.07 to 0.65) 78% (35% to 93%)
5 0.53 (0.22 to 1.24) 47% (124% to 78%)
Wahdan 1980a
EGY
1 Liquid formulation 3 0.06 (0.00 to 1.13) 94% (-13% to 100%)
2 0.06 (0.00 to 0.98) 94% (2% to 100%)
3 0.14 (0.02 to 1.12) 86% (-12% to 98%)
Levine 1987i CHL Cumulative inci-
dence 2.5 to 3 years
Enteric capsules 3 0.41 (0.28 to 0.91) 59% (9% to 72%)
Levine 1987ii CHL Cumulative inci-
dence 2.5 to 3 years
Enteric capsules 3 0.33 (0.18 to 0.63) 67% (82% to 37%)
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Table 1. Efficacy of Ty21a vaccine: unadjusted cluster-trial resultsa (Continued)
Levine 1990ii CHL Cumulative inci-
dence 2.5 to 3 years
Enteric capsules 3 0.63 (0.35 to 1.12) 37% (-12% to 65%)
Wahdan 1980a
EGY
Cumulative inci-
dence 2.5 to 3 years
Liquid formulation 3 0.04 (0.01 to 0.33) 96% (67% to 99%)
Levine 1990i CHL Cumulative inci-
dence 2.5 to 3 years
Liquid formulation 3 0.24 (0.13 to 0.47) 76% (53% to 87%)
Levine 1987iii CHL Cumulative inci-
dence 2.5 to 3 years
Gelatin capsules 3 0.69 (0.39 to 1.20) 31% (-20% to 61%)
Levine 1987iv CHL Cumulative inci-
dence 2.5 to 3 years
Gelatin capsules 3 0.81 (0.47 to 1.39) 19% (-39% to 53%)
Levine 1990i CHL Cumulative inci-
dence 2.5 to 3 years
Liquid preparation
vs enteric capsules
3 0.35 (0.21, 0.56) 65% (44% to 79%)
aFailure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect.
bRisk ratio with 95% confidence intervals.
Table 2. Cumulative efficacy of Ty21a vaccine at > 3 years: vaccine vs control
Trial Vaccine/
formulation
Length of follow-
up
Vaccine: incidence Control: incidence Efficacy (95%CI)a
Black 1990i CHL Ty21a: enteric cap-
sules, 2 doses
5 years 95/27,620 164/27,305 43% (26% to 55%)
Black 1990ii CHL Ty21a: enteric cap-
sules, 1 dose
5 years 200/27,618 164/27,305 -21% (-48% to 2%)
Levine 1987ii CHL Ty21a: enteric cap-
sules, 3 doses
7 years 50/22,170 131/21,906 62% (48% to 73%)
Levine 1990i CHL Ty21a: liquid for-
mulation, 3 doses
5 years 34/36,623 43/10,302 79% (65% to 87%)
aConfidence intervals.
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Table 3. Efficacy of Vi polysaccharide vaccine: unadjusted cluster-trial results by agea
Trial Year Age at baseline Typhoid episodes: Vi
vaccine
Typhoid episodes:
control
Efficacy (95% CI):
not adjusted
Khan 2012 PAK Cumulative
incidence at 2 years
2 to < 5 years 16/3154 13/3324 -30% (-183% to
40%)
5 to 16 years 14/10,084 36/10,669 59% (9% to 81%)
Sur 2009 IND Cumulative
incidence at 2 years
2 to < 5 years 5/1097 27/1095 82% (58% to 92%)
5 to < 15 years 21/4282 54/4584 59% (18% to 79%
≥ 15 years 8/13,490 15/13,125 48% (-44% to 81%)
a Failure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect.
Table 4. Adverse events following ViPS vaccine delivery: unadjusted results from cluster-randomized trialsa
Trial Adverse event Number of events: ViPS
vaccine
Number of events: control
group
Statistical significance
Khan 2012 PAK Fever 5/125 1/117 Not significant
Khan 2012 PAK Pain at injection site 4/125 1/117 Not significant
Sur 2009 IND Erythema 24/110 5/92 P < 0.001
Sur 2009 IND Pain at injection site 61/110 17/92 P < 0.001
Sur 2009 IND Fever 8/110 1/92 P = 0.04
a Failure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect.
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A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 typhoid fever typhoid* typhoid* typhoid$ typhoid fever
2 vaccine* typhoid-fever* typhoid fever TYPHOID FEVER vaccine*
3 1 and 2 salmonell* TYPHOID FEVER typhoid fever 1 and 2
4 - 1 or 2 or 3 salmonell* salmonell$ typhoid vaccine
5 - vaccine* 1 or 2 or 3 or 4 1 or 2 or 3 or 4 paratyphoid vaccine
6 - 4 and 5 vaccine* vaccine$ 3 or 4 or 5
7 - - 5 and 6 5 and 6 -
8 - - TYPHOID-PARATY-
PHOID VACCINES
TYPHOID VACCINE -
9 - - TY21 TYPHOID VAC-
CINE
TYPHOID-PARATY-
PHOID VACCINE
-
10 - - VI POLYSACCHARIDE
VACCINE, TYPHOID
7 or 8 or 9 -
11 - - 7 or 8 or 9 or 10 Limit 10 to human -
12 - - Limit 11 to human - -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins
2006); upper case: MeSH or EMTREE heading; lower case: free text term.
WH A T ’ S N E W
Last assessed as up-to-date: 17 June 2013.
Date Event Description
17 June 2013 New search has been performed This is an update of the review prepared by Fraser et
al (Fraser 2007a). This review update includes four new
trials, three evaluating the Vi polysaccharide vaccine (two
reporting on efficacy and adverse events, one reporting
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(Continued)
on adverse events only) and one evaluating the Vi-rEPA
vaccine (reporting adverse events)
17 June 2013 New citation required but conclusions have not changed Four new trials added.
H I S T O R Y
Protocol first published: Issue 4, 1998
Review first published: Issue 4, 1998
Date Event Description
22 August 2008 Amended Converted to new review format with minor editing.
26 April 2007 New citation required and conclusions have changed 2007, Issue 3: This review is an update of the original
version prepared by EA Engels and J Lau (Engels 1998a).
This review evaluates the evidence available for a new vac-
cine (Vi-rEPA) and includes 3 new efficacy trials that were
not included in Engels 1998a (1 evaluating the Vi-rEPA
and 2 evaluating the Vi polysaccharide vaccine). It would
also have included head-on comparisons of the different
types of vaccines (not included in Engels 1998a) had these
direct comparisons been conducted. Since Engels 1998a
was published, killed whole-cell vaccines are no longer in
use and therefore are not included in this review
C O N T R I B U T I O N S O F A U T H O R S
E Anwar: data collection and management, analysis, interpretation of results and review writing. E Goldberg: data collection. M Paul:
data extraction and review writing. A Fraser: review writing, CJ Acosta: review writing. L Leibovici: review writing.
D E C L A R A T I O N S O F I N T E R E S T
For all review authors, none known.
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S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
• University of Liverpool, UK.
External sources
• Department for International Development (DFID), UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Randomized Controlled Trials as Topic; Salmonella typhi [immunology]; Typhoid Fever [immunology; ∗prevention & control];
Typhoid-ParatyphoidVaccines [administration&dosage; ∗ therapeutic use]; Vaccines, Attenuated [administration&dosage; therapeutic
use]
MeSH check words
Adolescent; Adult; Child; Child, Preschool; Humans
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